

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 213/34, A61K 31/44</b>		<b>A1</b>	(11) International Publication Number: <b>WO 98/03484</b>
			(43) International Publication Date: 29 January 1998 (29.01.98)
(21) International Application Number: <b>PCT/CA97/00486</b>		(74) Agent: MURPHY, Kevin, P.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College, Montreal, Quebec H3A 2Y3 (CA).	
(22) International Filing Date: 8 July 1997 (08.07.97)			
(30) Priority Data:		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
60/022,128 18 July 1996 (18.07.96) US 9616126.0 1 August 1996 (01.08.96) GB 60/027,139 1 October 1996 (01.10.96) US 9621420.0 15 October 1996 (15.10.96) GB 60/041,814 8 April 1997 (08.04.97) US 9709291.0 7 May 1997 (07.05.97) GB			
(71) Applicant (for all designated States except US): MERCK FROSST CANADA INC. [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA).		Published With international search report.	
(72) Inventors; and			
(75) Inventors/Applicants (for US only): DUBE, Daniel [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). FORTIN, Rejean [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). FRIESEN, Richard [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). WANG, Zhaoyin [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). GAUTHIER, Jacques, Yves [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA).			

(54) Title: SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS

## (57) Abstract

The invention encompasses the novel compound of formula (I) as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of formula (I).



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

**TITLE OF THE INVENTION****SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS****5    BACKGROUND OF THE INVENTION**

This invention relates to methods of treating cyclooxygenase mediated diseases and certain pharmaceutical compositions therefor.

10        Non-steroidal, antiinflammatory drugs exert most of their antiinflammatory, analgesic and antipyretic activity and inhibit hormone-induced uterine contractions and certain types of cancer growth through inhibition of prostaglandin G/H synthase, also known as cyclooxygenase. Initially, only one form of cyclooxygenase was known, this corresponding to cyclooxygenase-1 (COX-1) or the constitutive  
15        enzyme, as originally identified in bovine seminal vesicles. More recently the gene for a second inducible form of cyclooxygenase, cyclooxygenase-2 (COX-2) has been cloned, sequenced and characterized initially from chicken, murine and human sources. This enzyme is distinct from the COX-1 which has been cloned, sequenced  
20        and characterized from various sources including the sheep, the mouse and man. The second form of cyclooxygenase, COX-2, is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. As prostaglandins have both physiological and pathological roles, we have concluded that the  
25        constitutive enzyme, COX-1, is responsible, in large part, for endogenous basal release of prostaglandins and hence is important in their physiological functions such as the maintenance of gastrointestinal integrity and renal blood flow. In contrast, we have concluded that the inducible form, COX-2, is mainly responsible for the pathological  
30        effects of prostaglandins where rapid induction of the enzyme would occur in response to such agents as inflammatory agents, hormones, growth factors, and cytokines. Thus, a selective inhibitor of COX-2 will have similar antiinflammatory, antipyretic and analgesic properties to a conventional non-steroidal antiinflammatory drug, and in addition

- 2 -

would inhibit hormone-induced uterine contractions and have potential anti-cancer effects, but will have a diminished ability to induce some of the mechanism-based side effects. In particular, such a compound should have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and possibly a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.

Furthermore, such a compound will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labour, asthma and eosinophil related disorders. It will also be of use in the treatment of Alzheimer's disease, for decreasing bone loss particularly in postmenopausal women (i.e. treatment of osteoporosis) and for the treatment of glaucoma.


The potential utilities of selective cyclooxygenase-2 inhibitors are discussed in the following articles:

- 1. John Vane, "Towards a better aspirin" in Nature, Vol. 367, pp. 215-216, 1994.
- 2. Bruno Battistini, Regina Botting and Y.S. Bakhle, "COX-1 and COX-2: Toward the Development of More Selective NSAIDs" in Drug News and Perspectives, Vol. 7, pp. 501-512, 1994.
- 3. David B. Reitz and Karen Seibert, "Selective Cyclooxygenase Inhibitors" in Annual Reports in Medicinal Chemistry, James A. Bristol, Editor, Vol. 30, pp. 179-188, 1995.
- 4. Don E. Griswold and Jerry L. Adams, "Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date" in Medicinal Research Reviews, Vol. 16, pp. 181-206, 1996.

WO 96/10012 (DuPont Merck, April 4, 1996) discloses compounds represented by Formula A as being useful in the treatment of COX-2 mediated diseases, by virtue of their selective inhibition of COX-2 rather than COX-1. We have now discovered that a subset of the compounds represented by A, in which -J-K-L- is -NCHCH-, X is a bond, R<sup>1</sup> is aromatic and R<sup>3</sup> and R<sup>4</sup> are not both hydrogen show

- 3 -

unexpectedly superior selectivity for the inhibition of COX-2 over COX-1 and/or superior potency as compared to the closest species disclosed in 96/10012. This subset of compounds is the subject of the present invention and is represented by Formula I.




Of the over 175 specific compounds disclosed in WO 96/10012, only 4 of them are pyridines, and none of these latter contain a substituent ( $R^3$  or  $R^4$  in A) on the pyridine ring.

WO 96/16934 (Searle, June 6, 1996) discloses compounds represented by structure B as being useful for the treatment of inflammation and related disorders. Chemically, these compounds differ from those of the present invention in that the central of the three aromatic rings is benzene rather than pyridine.

## 15 SUMMARY OF THE INVENTION

The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.




I

- 4 -

The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.

5 DETAILED DESCRIPTION OF THE INVENTION

The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I



I

wherein:

R¹ is selected from the group consisting of

- 15 (a) CH<sub>3</sub>,  
(b) NH<sub>2</sub>,  
(c) NHC(O)CF<sub>3</sub>,  
(d) NHCH<sub>3</sub>;

Ar is a mono-, di-, or trisubstituted phenyl or pyridinyl (or the N-oxide thereof), wherein the substituents are chosen from the group consisting

- 20 of  
(a) hydrogen,  
(b) halo,  
(c) C<sub>1</sub>-6alkoxy,  
(d) C<sub>1</sub>-6alkylthio,  
25 (e) CN,  
(f) C<sub>1</sub>-6alkyl,  
(g) C<sub>1</sub>-6fluoroalkyl,  
(h) N<sub>3</sub>,

- 5 -

- (i)  $-\text{CO}_2\text{R}^3$ ,  
 (j) hydroxy,  
 (k)  $-\text{C}(\text{R}^4)(\text{R}^5)-\text{OH}$ ,  
 (l)  $-\text{C}_{1-6}\text{alkyl}-\text{CO}_2-\text{R}^6$ ,  
 5 (m)  $\text{C}_{1-6}\text{fluoroalkoxy}$ ;

$\text{R}^2$  is chosen from the group consisting of

- (a) halo,  
 (b)  $\text{C}_{1-6}\text{alkoxy}$ ,  
 (c)  $\text{C}_{1-6}\text{alkylthio}$ ,  
 10 (d)  $\text{CN}$ ,  
 (e)  $\text{C}_{1-6}\text{alkyl}$ ,  
 (f)  $\text{C}_{1-6}\text{fluoroalkyl}$ ,  
 (g)  $\text{N}_3$ ,  
 (h)  $-\text{CO}_2\text{R}^7$ ,  
 15 (i) hydroxy,  
 (j)  $-\text{C}(\text{R}^8)(\text{R}^9)-\text{OH}$ ,  
 (k)  $-\text{C}_{1-6}\text{alkyl}-\text{CO}_2-\text{R}^{10}$ ,  
 (l)  $\text{C}_{1-6}\text{fluoroalkoxy}$ ,  
 (m)  $\text{NO}_2$ ,  
 20 (n)  $\text{NR}^{11}\text{R}^{12}$ , and  
 (o)  $\text{NHCOR}^{13}$ ,

$\text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}$ , are each independently chosen from the group consisting of

- (a) hydrogen, and  
 25 (b)  $\text{C}_{1-6}\text{alkyl}$ ,

or  $\text{R}^4$  and  $\text{R}^5$ ,  $\text{R}^8$  and  $\text{R}^9$  or  $\text{R}^{11}$  and  $\text{R}^{12}$  together with the atom to which they are attached form a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms.

- Apt alkyl groups include methyl, ethyl, n-propyl, iso-propyl and butyl, pentyl and hexyl groups. A favoured alkyl group is the methyl group. In general  $\text{R}^4$  and  $\text{R}^5$ ,  $\text{R}^8$  and  $\text{R}^9$  and  $\text{R}^{11}$  and  $\text{R}^{12}$  are not residues of the above-mentioned monocyclic rings. When 'alkyl' is part of a composite term such as alkoxy, alkylthio, fluoroalkyl, fluoroalkoxy then the above meaning of alkyl refers also to the
- 30



- 6 -

composite term.

5 A preferred sub-genus of formula I is that wherein Ar is a mono-, or disubstituted pyridinyl. Within this sub-genus, the 3-pyridinyl isomers, such as those of formula Ic, are particularly preferred.

When Ar is di-substituted phenyl is particularly apt that one or both of the substituents are hydrogen.

Another preferred sub-genus of formula I is that wherein Ar is a mono- or disubstituted phenyl.

10 When Ar is di-substituted phenyl it is particularly apt that one of the substituents is hydrogen or fluorine and the second is hydrogen, fluorine, chlorine, methyl, methoxyl or trifluoromethyl.

15 Another preferred sub-genus of formula I is that wherein R<sup>1</sup> is CH<sub>3</sub> or NH<sub>2</sub>. Generally, CH<sub>3</sub> is preferred for COX-2 specificity and NH<sub>2</sub> is preferred for potency.


Another preferred sub-genus of formula I is that wherein R<sup>2</sup> is halo, CH<sub>3</sub> or CF<sub>3</sub>.

20 Another preferred sub-genus of formula I is that wherein the substituents on Ar are chosen from the group consisting of

- (a) hydrogen,
- (b) halo,
- (c) C<sub>1</sub>-4alkoxy,
- (d) C<sub>1</sub>-4alkylthio,
- 25 (e) C<sub>1</sub>-4alkyl,
- (f) CF<sub>3</sub>, and
- (g) CN.

30 In one aspect the invention is directed to compounds of formula I

- 7 -



wherein:

$R^1$  is selected from the group consisting of

- 5           (a)  $CH_3$ ,  
              (b)  $NH_2$ ,  
              (c)  $NHC(O)CF_3$ ,  
              (d)  $NHCH_3$ ;

10       Ar is a mono-, di-, or trisubstituted pyridinyl (or the N-oxide thereof),  
       wherein the substituents are chosen from the group consisting of

- (a) hydrogen,  
           (b) halo,  
           (c) C1-6alkoxy,  
           (d) C1-6alkylthio,  
 15       (e) CN,  
           (f) C1-6alkyl,  
           (g) C1-6fluoroalkyl,  
           (h)  $N_3$ ,  
           (i)  $-CO_2R^3$ ,  
 20       (j) hydroxy,  
           (k)  $-C(R^4)(R^5)-OH$ ,  
           (l)  $-C1-6alkyl-CO_2-R^6$ ,  
           (m) C1-6fluoroalkoxy;

$R^2$  is chosen from the group consisting of

- 25       (a) halo,  
           (b) C1-6alkoxy,  
           (c) C1-6alkylthio,  
           (d) C1-6alkyl,


- 8 -

- 5 (e) N<sub>3</sub>,  
(f) -CO<sub>2</sub>H,  
(g) hydroxy,  
(h) C<sub>1</sub>-6fluoroalkoxy,  
(i) NO<sub>2</sub>,  
(j) NR<sup>11</sup>R<sup>12</sup>, and  
(k) NHCOR<sup>13</sup>,  
R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, are each independantly chosen from  
the group consisting of  
10 (a) hydrogen, and  
(b) C<sub>1</sub>-6alkyl,  
or R<sup>4</sup> and R<sup>5</sup> or R<sup>11</sup> and R<sup>12</sup> together with the atom to which they are  
attached form a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms.

- 9 -

Within this aspect there is a genus of compounds of formula

Ic



wherein:

5

$\text{R}^1$  is selected from the group consisting of

- (a)  $\text{CH}_3$ ,
- (b)  $\text{NH}_2$ ,

$\text{R}^2$  is chosen from the group consisting of

10

- (a) chloro,
- (b) methyl,

and wherein there may be one, two or three groups  $\text{X}$  independently selected from the group consisting of

15


- (a) hydrogen,
- (b) halo,
- (c)  $\text{C}_1$ -4alkoxy,
- (d)  $\text{C}_1$ -4alkylthio,
- (e)  $\text{CN}$ ,
- (f)  $\text{C}_1$ -4alkyl,

20

- (g)  $\text{CF}_3$ .

- 10 -

Within this genus of compounds of formula Ic



there is a sub-genus wherein:

5  $R^1$  is selected from the group consisting of

- (a)  $CH_3$ ,
- (b)  $NH_2$ ,


$R^2$  is chloro,

10 wherein there is one group X independently selected from the group consisting of

- (a) hydrogen,
- (b) F or Cl,
- (c) methyl,
- (d) ethyl.

15

Within this genus of compounds of formula Ic



there is a sub-genus wherein:

- 11 -

R<sup>1</sup> is selected from the group consisting of

- (a) CH<sub>3</sub>,
- (b) NH<sub>2</sub>,

R<sup>2</sup> is chloro,

5 wherein there is one group X independently selected from the group consisting of

- (a) hydrogen,
- (b) F or Cl,
- (c) methyl.

10

Preferred compounds of formula I and Ic include those wherein R<sup>2</sup> is halo, especially chloro.

Preferred compounds of formula I and Ic include those wherein Ar is 3-pyridinyl and X is hydrogen or C<sub>1</sub>-3alkyl, especially

15 hydrogen, p-methyl and p-ethyl.

Illustrating the invention are the following compounds:

3-(4-Methylsulfonyl)phenyl-2-phenyl-5-trifluoromethylpyridine;

20

2-(3-Chlorophenyl)-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl-pyridine;

2-(4-Chlorophenyl)-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl-pyridine;

25

2-(4-Fluorophenyl)-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl-pyridine;

3-(4-Methylsulfonyl)phenyl-2-(3-pyridinyl)-5-trifluoromethylpyridine;

5-Methyl-3-(4-methylsulfonyl)phenyl-2-phenylpyridine;

2-(4-Chlorophenyl)-5-methyl-3-(4-methylsulfonyl)phenylpyridine;

30

5-Methyl-3-(4-methylsulfonyl)phenyl-2-(3-pyridinyl)pyridine;

5-Chloro-2-(4-chlorophenyl)-3-(4-methylsulfonyl)phenylpyridine;

5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-pyridinyl)

- 12 -

pyridine;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridinyl)  
pyridine;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(4-pyridinyl)  
5  
pyridine;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-  
pyridinyl)pyridine;  
2-(4-Chlorophenyl)-3-(4-methylsulfonyl)phenylpyridinyl-  
5-carboxylic acid methyl ester;  
10 2-(4-Chlorophenyl)-3-(4-methylsulfonyl)phenylpyridinyl-  
5-carboxylic acid;  
5-Cyano-2-(4-chlorophenyl)-3-(4-methylsulfonyl)  
phenylpyridine;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridyl)pyridine  
15 hydromethanesulfonate;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridyl)pyridine  
hydrochloride;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-  
pyridinyl)pyridine Hydrochloride;  
20 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-ethyl-5-  
pyridinyl)pyridine; and  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-ethyl-5-  
pyridinyl)pyridine hydromethanesulfonate.

25 Preferred compounds of formula I and Ic include those  
wherein R<sup>1</sup> is methyl or NH<sub>2</sub>, especially methyl.

In another aspect the invention also encompasses a  
pharmaceutical composition for treating an inflammatory disease  
susceptable to treatment with an non-steroidal anti-inflammatory agent  
30 comprising:  
a non-toxic therapeutically effective amount of a compound of formula I  
and a pharmaceutically acceptable carrier.

In another aspect the invention also encompasses a  
pharmaceutical composition for treating cyclooxygenase mediated

- 13 -

diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:  
a non-toxic therapeutically effective amount of a compound of formula I and a pharmaceutically acceptable carrier.

5           In another aspect the invention also encompasses a method of treating an inflammatory disease susceptible to treatment with an non-steroidal anti-inflammatory agent comprising:  
administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of formula I and a  
10       pharmaceutically acceptable carrier.

          In another aspect the invention also encompasses a method of treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:  
15       administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of formula I.

          In another aspect the invention also encompasses the use of a compound of formula I or a pharmaceutical composition in the manufacture of a medicament for the treatment of an inflammatory  
20       disease susceptible to treatment with an a non-steroidal anti-inflammatory agent.

The invention is illustrated by Example 1 to 56.

25           The following abbreviations have the indicated meanings:

AA	=	arachidonic acid
Ac	=	acetyl
AIBN	=	2,2'-azobisisobutyronitrile
30    BHT	=	butylated hydroxytoluene
Bn	=	benzyl
CSA	=	camphor sulfonic acid (racemic)
dba	=	dibenzylideneacetone
DMAP	=	4-(dimethylamino)pyridine



- 14 -

	DMF	=	N,N-dimethylformamide
	DMSO	=	dimethyl sulfoxide
	EDTA	=	ethylenediaminetetraacetic acid
	ESA	=	ethane sulfonic acid
5	Et <sub>3</sub> N	=	triethylamine
	HBSS	=	Hanks balanced salt solution
	HEPES	=	N-[2-Hydroxyethyl]piperazine-N <sup>1</sup> -[2-ethanesulfonic acid]
	HWB	=	human whole blood
10	KHMDS	=	potassium hexamethyldisilazane
	LDA	=	lithium diisopropylamide
	LPS	=	lipopolysaccharide
	mCPBA	=	m-chloroperbenzoic acid
	MMPP	=	magnesium monoperoxyphthalate
15	Ms	=	methanesulfonyl = mesyl
	MsO	=	methanesulfonate = mesylate
	NBS	=	N-bromosuccinimide
	NCS	=	N-chlorosuccinimide
	NIS	=	N-iodosuccinimide
20	NMO	=	N-methylmorpholine-N-oxide
	NMP	=	N-methylpyrrolidone
	NSAID	=	non-steroidal anti-inflammatory drug
	oxone®	=	2KHSO <sub>5</sub> •KHSO <sub>4</sub> •K <sub>2</sub> SO <sub>4</sub>
	PCC	=	pyridinium chlorochromate
25	PDC	=	pyridinium dichromate
	PEG	=	polyethyleneglycol
	Ph	=	phenyl
	pyr	=	pyridinyl
	r.t.	=	room temperature
30	rac.	=	racemic
	Tf	=	trifluoromethanesulfonyl = triflyl
	TfO	=	trifluoromethanesulfonate = triflate
	THF	=	tetrahydrofuran
	TLC	=	thin layer chromatography

- 15 -

	Ts	=	p-toluenesulfonyl = tosyl
	TsO	=	p-toluenesulfonate = tosylate
	Tz	=	1H (or 2H)-tetrazol-5-yl
	SO <sub>2</sub> Me	=	methyl sulfone
5	SO <sub>2</sub> NH <sub>2</sub>	=	sulfonamide

## Alkyl group abbreviations

	Me	=	methyl
	Et	=	ethyl
10	n-Pr	=	normal propyl
	i-Pr	=	isopropyl
	n-Bu	=	normal butyl
	i-Bu	=	isobutyl
	s-Bu	=	secondary butyl
15	t-Bu	=	tertiary butyl
	c-Pr	=	cyclopropyl
	c-Bu	=	cyclobutyl
	c-Pen	=	cyclopentyl
	c-Hex	=	cyclohexyl

20

## Dose Abbreviations

	bid	=	bis in die = twice daily
	qid	=	quater in die = four times a day
	tid	=	ter in die = three times a day

25

For purposes of this specification alkyl is defined to include linear, branched and cyclic structures, with the indicated number of carbon atoms. Examples of alkyl are methyl, ethyl, propyl, s- and t-butyl, butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclohexylmethyl and the like. Similarly, alkoxy and alkylthio mean linear, branched and cyclic structures, with the indicated number of carbon atoms.

30

For purposes of this specification fluoroalkyl means alkyl groups of the indicated number of carbon atoms in which one hydrogen

- 16 -

or more is replaced by fluorine. Examples are -CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>F, -CH<sub>2</sub>CF<sub>3</sub>, c-Pr-F<sub>5</sub>, c-Hex-F<sub>11</sub> and the like. Similarly, fluoroalkoxy means linear, branched and cyclic structures, with the indicated number of carbon atoms.

5 For purposes of this specification, in situations in which a term occurs two or more times, the definition of the term in each occurrence is independent of the definition in each additional occurrence.

10 I. For purposes of this specification halo means F, Cl, Br, or

In another embodiment, the invention encompasses pharmaceutical compositions for inhibiting COX-2 and for treating COX-2 mediated diseases as disclosed herein comprising a pharmaceutically acceptable carrier and non-toxic therapeutically effective amount of a compound of formula I as described above.

15 In yet another embodiment, the invention encompasses a method of inhibiting cyclooxygenase and treating cyclooxygenase mediated diseases, advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 as disclosed herein comprising:  
20 administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I as disclosed herein.

25 Optical Isomers - Diastereomers - Geometric Isomers

Some of the compounds described herein contain one or more asymmetric centres and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved,  
30 enantiomerically pure forms and pharmaceutically acceptable salts thereof.

Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

- 17 -

Salts

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, N-methylglucamine, glucamine, glucosamine, histidine, hydrabamine, N-(2-hydroxyethyl)piperidine, N-(2-hydroxyethyl)pyrrolidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, adipic, aspartic, 1,5-naphthalenedisulfonic, benzenesulfonic, benzoic, camphorsulfonic, citric, 1,2-ethanedisulfonic, ethanesulfonic, ethylenediaminetetraacetic, fumaric, glucoheptonic, gluconic, glutamic, hydriodic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, 2-naphthalenesulfonic, nitric, oxalic, pamoic, pantothenic, phosphoric, pivalic, propionic, salicylic, stearic,

- 18 -

succinic, sulfuric, tartaric, p-toluenesulfonic acid, undecanoic, 10-undecenoic, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, methanesulfonic, phosphoric, sulfuric and tartaric acids.

- 5                   It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.

#### Utilities

- 10                   The Compound of Formula I is useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis,  
15                   including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries, following surgical and dental procedures. In addition, such a compound may inhibit cellular neoplastic transformations and metastatic tumour growth and hence can be used in the treatment of cancer.  
20                   Compound 1 may also be of use in the treatment and/or prevention of cyclooxygenase-mediated proliferative disorders such as may occur in diabetic retinopathy and tumour angiogenesis.

- Compound I will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids  
25                   and hence may be of use in the treatment of dysmenorrhea, premature labour, asthma and eosinophil related disorders. It will also be of use in the treatment of Alzheimer's disease, for decreasing bone loss particularly in postmenopausal women (i.e. treatment of osteoporosis) and for treatment of glaucoma.

- 30                   By virtue of its high inhibitory activity against COX-2 and/or its specificity for inhibiting COX-2 over COX-1, compound I will prove useful as an alternative to conventional NSAID'S, particularly where such non-steroidal antiinflammatory drugs may be contra-indicated such as in patients with peptic ulcers, gastritis, regional

- 19 -

enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anaemia such as hypoprothrombinemia, haemophilia or other bleeding problems; kidney disease; those prior to surgery or taking  
5 anticoagulants.

### Pharmaceutical Compositions

For the treatment of any of these cyclooxygenase mediated diseases compound I may be administered orally, topically, parenterally,  
10 by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such  
15 as mice, rats, horses, cattle, sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans. The compounds of the instant invention are particularly well suited for horses.

As indicated above, pharmaceutical compositions for treating COX-2 mediated diseases as defined may optionally include one  
20 or more ingredients as listed above.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible  
25 powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring  
agents, colouring agents and preserving agents in order to provide  
30 pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium

- 20 -

phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by  
5 known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108;  
10 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or  
15 kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in  
20 admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethycellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide,  
25 for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol  
30 such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, benzyl alcohol, one or

- 21 -

more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which



- 22 -

have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed  
5 are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or  
10 diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Compound of Formula I may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-  
15 irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the compound of Formula I are employed.  
20 (For purposes of this application, topical application shall include mouth washes and gargles.) Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.

## 25 Dose Ranges

Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation may be effectively  
30 treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary

- 23 -

depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

#### Combinations with Other Drugs

Similarly, compound of Formula I, will be useful as a partial or complete substitute for conventional NSAID'S in preparations wherein they are presently co-administered with other agents or ingredients. Thus in further aspects, the invention encompasses pharmaceutical compositions for treating COX-2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including acetaminophen or phenacetin; a potentiator including caffeine; an H<sub>2</sub>-antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levodesoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; a prostaglandin including misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol; a diuretic; a sedating or non-sedating antihistamine. In addition the invention encompasses a method of treating cyclooxygenase mediated

- 24 -

diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of the compound of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.

5

### Methods of Synthesis

The compounds of Formula I of the present invention can be prepared according to the synthetic routes outlined in Schemes 1 to 2 and by following the methods described therein.


10

### SCHEME 1

The pyridines of Formula Ia and Ib may be prepared in a multi-step sequence from the requisite 2-aminopyridine II. Initial  
15 bromination of II with bromine in acetic acid provides the bromide III. A palladium-catalyzed coupling of III with 4-(methylthio)phenylboronic acid in the presence of a suitable base, such as sodium carbonate, provides the sulfide IV which can be oxidized using one of several oxidants, such as MMPP, oxone®, or OsO<sub>4</sub>/NMO to the  
20 corresponding sulfone V. The amino pyridine V can be converted to the halide VI via one of several methods. For example, treatment of V with sodium nitrite in the presence of HCl and bromine provides the bromide VI (X = Br). Alternatively, treatment of V with sodium nitrite and HCl followed by reaction with POCl<sub>3</sub> affords the  
25 corresponding chloride VI (X = Cl). A second palladium-catalyzed coupling of VI with an appropriately substituted metalated aromatic, such as an aryl boronic acid or an aryl stannane, provides the pyridine of Formula Ia. Suitable modification of the R<sup>2</sup> substituent in Ia provides additional examples of Ia. For example when R<sup>2</sup> = Me, oxidation with an oxidant such as KMnO<sub>4</sub> provides the corresponding  
30 acid (Ia R<sup>2</sup> = CO<sub>2</sub>H) which can then be converted to the methyl ester (Ia R<sup>2</sup> = CO<sub>2</sub>Me), using a reagent such as diazomethane. Alternatively, treatment of the acid with chlorosulfonylisocyanate and DMF provides the nitrile (Ia R<sup>2</sup> = CN). The pyridine methyl sulfones Ia can be

- 25 -

converted to the corresponding pyridine sulfonamides **Ib** by using procedures described in the literature (Huang et. al. *Tetrahedron Lett.* 1994, 39, 7201).




- 26 -

SCHEME 2

The 2-halopyridines VI of Scheme 1 can also be prepared in a multi-step process from the appropriate 2-hydroxypyridines VII.

- 5 First, treatment of VII with bromine in acetic acid provides the bromide VIII. Subsequent reaction of VIII with benzyl bromide in the presence of a base such as silver carbonate yields the benzyl ether IX which can be converted to the sulfone X via a sequence of reactions similar to those described for the conversion of bromide III to V in
- 10 Scheme 1. The benzyl protecting group can be removed by treatment of IX with an acid such as trifluoroacetic acid to afford the hydroxypyridine X. Heating X with POBr<sub>3</sub> or POCl<sub>3</sub> provides the corresponding 2-halopyridines VI (X = Br, Cl) of Scheme 1.




- 27 -

REPRESENTATIVE COMPOUNDS

Tables 1 and 2 illustrate compounds of formula Ia and Ib,  
which are representative of the present invention.

- 28 -

Table 1




1a

	Ex.	$R^2$	Ar
5	1	$CF_3$	Ph
	2	$CF_3$	3- $ClC_6H_4$
	3	$CF_3$	4- $ClC_6H_4$
	4	$CF_3$	4- $FC_6H_4$
10	5	$CF_3$	2-( $CMe_2OH$ ) $C_6H_4$
	6	$CF_3$	3-( $CMe_2OH$ ) $C_6H_4$
	7	$CF_3$	3-pyr
	8	$CF_3$	5-(2-Me)pyr
	9	$CF_3$	5-(3-Br)pyr
15	10	$CF_3$	5-(3-Cl)pyr
	11	$CF_3$	5-(2-OMe)pyr
	12	$CF_3$	2-(5-Br)pyr
	13	Me	Ph
	14	Me	4- $ClC_6H_4$
20	15	Me	3-pyr
	16	Cl	Ph
	17	Cl	4- $ClC_6H_4$
	18	Cl	2-( $CMe_2OH$ ) $C_6H_4$
	19	Cl	3-( $CMe_2OH$ ) $C_6H_4$
	20	Cl	2-pyr
25	21	Cl	3-pyr
	22	Cl	4-pyr
	23	Cl	5-(2-Me)pyr
	24	Cl	5-(3-Br)pyr
	25	Cl	5-(3-Cl)pyr

- 29 -

Table 1 (cont'd.)




1a

	Ex.	$R^2$	Ar
5	26	Cl	5-(2-OMe)pyr
	27	Cl	2-(5-Br)pyr
	28	F	Ph
	29	F	3-pyr
10	30	F	5-(2-Me)pyr
	31	Br	Ph
	32	Br	3-pyr
	33	Br	5-(2-Me)pyr
	34	NO <sub>2</sub>	Ph
15	35	NO <sub>2</sub>	3-pyr
	36	NO <sub>2</sub>	5-(2-Me)pyr
	37	OMe	Ph
	38	OMe	3-pyr
	39	OMe	5-(2-Me)pyr
20	40	NHCOMe	Ph
	41	NHCOMe	3-pyr
	42	NHCOMe	5-(2-Me)pyr
	43	CO <sub>2</sub> Me	4-ClC <sub>6</sub> H <sub>4</sub>
	44	CO <sub>2</sub> H	4-ClC <sub>6</sub> H <sub>4</sub>
25	45	CN	4-ClC <sub>6</sub> H <sub>4</sub>
	46	Cl	3-pyr•MeSO <sub>3</sub> H
	47	Cl	3-pyr•HCl
	57	Cl	3-pyr•CSA
30	58	Cl	3-pyr•ESA
	59	Cl	5-(2-Me)pyr•HCl
	60	Cl	5-(2-CH <sub>2</sub> OH)pyr



- 30 -

Table 1 (cont'd.)




1a

	Ex.	$R^2$	Ar
5	61	Cl	5-(2-CO <sub>2</sub> H)pyr
	62	Cl	5-(2-Me)pyr-N-oxide
	63	Cl	5-(3-Me)pyr
	64	Cl	3-(4-Me)pyr
10	65	Cl	3-(2-Me)pyr
	66	Cl	3-(2-Et)pyr
	67	Cl	3-(2-c-Pr)pyr
	68	Me	3-pyr•HCl
	69	CN	3-pyr
15	70	CN	5-(2-Me)pyr
	71	Cl	5-(2-Et)pyr
	72	Cl	5-(2-Et)pyr-MeSO <sub>3</sub> H
	73	Cl	5-(2-c-Pr)pyr
	74	Cl	3-(2,6-Me <sub>2</sub> )pyr

20

- 31 -

TABLE 2

1b

	Ex.	$R^2$	Ar
5	48	CF <sub>3</sub>	Ph
	49	CF <sub>3</sub>	4-ClC <sub>6</sub> H <sub>4</sub>
	50	CF <sub>3</sub>	4-FC <sub>6</sub> H <sub>4</sub>
10	51	CF <sub>3</sub>	3-pyr
	52	Me	Ph
	53	Me	4-ClC <sub>6</sub> H <sub>4</sub>
	54	Cl	3-pyr
	55	Cl	5-(2-Me)pyr
15	56	CN	4-ClC <sub>6</sub> H <sub>4</sub>

- 32 -

### ASSAYS FOR DETERMINING BIOLOGICAL ACTIVITY

The compound of Formula I can be tested using the following assays to determine their COX-2 inhibiting activity.

5

#### INHIBITION OF CYCLOOXYGENASE ACTIVITY

Compounds are tested as inhibitors of cyclooxygenase activity in whole cell cyclooxygenase assays. Both of these assays measure prostaglandin E<sub>2</sub> synthesis in response to AA, using a  
10 radioimmunoassay. Cells used for these assays are human osteosarcoma 143 cells (which specifically express COX-2) and human U-937 cells (which specifically express COX-1). In these assays, 100% activity is defined as the difference between prostaglandin E<sub>2</sub> synthesis in the absence and presence of arachidonate.

15

#### Whole Cell Assays

For cyclooxygenase assays, osteosarcoma cells are cultured in 1 mL of media in 24-well multidishes (Nunc) until confluent ( $1-2 \times 10^5$  cells/well). U-937 cells are grown in spinner flasks and  
20 resuspended to a final density of  $1.5 \times 10^6$  cells/mL in 24-well multidishes (Nunc). Following washing and resuspension of osteosarcoma and U-937 cells in 1 mL of HBSS, 1  $\mu$ L of a DMSO solution of test compound or DMSO vehicle is added, and samples gently mixed. All assays are performed in triplicate. Samples are then  
25 incubated for 5 or 15 minutes at 37°C, prior to the addition of AA. AA (peroxide-free, Cayman Chemical) is prepared as a 10 mM stock solution in ethanol and further diluted 10-fold in HBSS. An aliquot of 10  $\mu$ L of this diluted solution is added to the cells to give a final AA concentration of 10  $\mu$ M. Control samples are incubated with ethanol  
30 vehicle instead of AA. Samples are again gently mixed and incubated for a further 10 min. at 37°C. For osteosarcoma cells, reactions are then stopped by the addition of 100  $\mu$ L of 1N HCl, with mixing and by the rapid removal of the solution from cell monolayers. For U-937 cells, reactions are stopped by the addition of 100  $\mu$ L of 1N HCl, with

- 33 -

mixing. Samples are then neutralized by the addition of 100  $\mu$ L of 1N NaOH and PGE<sub>2</sub> levels measured by radioimmunoassay.

Whole cell assays for COX-2 and COX-1 using CHO transfected cell lines

Chinese hamster ovary (CHO) cell lines which have been stably transfected with an eukaryotic expression vector pCDNAIII containing either the human COX-1 or COX-2 cDNA's are used for the assay. These cell lines are referred to as CHO [hCOX-1] and CHO [hCOX-2], respectively. For cyclooxygenase assays, CHO[hCOX-1] cells from suspension cultures and CHO[hCOX-2] cells prepared by trypsinization of adherent cultures are harvested by centrifugation (300 x g, 10 min) and washed once in HBSS containing 15 mM HEPES, pH 7.4, and resuspended in HBSS, 15 mM HEPES, pH 7.4, at a cell concentration of  $1.5 \times 10^6$  cells/ml. Drugs to be tested are dissolved in DMSO to 66.7-fold the highest test drug concentration. Compounds are typically tested at 8 concentrations in duplicate using serial 3-fold serial dilutions in DMSO of the highest drug concentration. Cells ( $0.3 \times 10^6$  cells in 200  $\mu$ l) are preincubated with 3  $\mu$ l of the test drug or DMSO vehicle for 15 min at 37°C. Working solutions of peroxide-free AA (5.5  $\mu$ M and 110  $\mu$ M AA for the CHO [hCOX-1] and CHO [COX-2] assays, respectively) are prepared by a 10-fold dilution of a concentrated AA solution in ethanol into HBSS containing 15 mM HEPES, pH 7.4. Cells are then challenged in the presence or absence of drug with the AA/HBSS solution to yield a final concentration of 0.5  $\mu$ M AA in the CHO[hCOX-1] assay and a final concentration of 10  $\mu$ M AA in the CHO[hCOX-2] assay. The reaction is terminated by the addition of 10  $\mu$ l 1 N HCl followed by neutralization with 20  $\mu$ l of 0.5 N NaOH. The samples are centrifuged at 300 x g at 4°C for 10 min, and an aliquot of the clarified supernatant is appropriately diluted for the determination of PGE<sub>2</sub> levels using an enzyme-linked immunoassay for PGE<sub>2</sub> (Correlate PGE<sub>2</sub> enzyme immunoassay kit, Assay Designs, Inc.). Cyclooxygenase activity in the absence of test compounds is determined as the difference in PGE<sub>2</sub> levels of cells challenged with AA

- 34 -

versus the PGE<sub>2</sub> levels in cells mock-challenged with ethanol vehicle. Inhibition of PGE<sub>2</sub> synthesis by test compounds is calculated as a percentage of the activity in the presence of drug versus the activity in the positive control samples.

5

Assay of COX-1 Activity from U937 cell microsomes

U 937 cells are pelleted by centrifugation at 500 x g for 5 min and washed once with phosphate-buffered saline and repelleted. Cells are resuspended in homogenization buffer consisting of 0.1 M  
10 Tris-HCl, pH 7.4, 10 mM EDTA, 2 µg/ml leupeptin, 2 µg/ml soybean trypsin inhibitor, 2 µg/ml aprotinin and 1 mM phenyl methyl sulfonyl fluoride. The cell suspension is sonicated 4 times for 10 sec and is centrifuged at 10,000 x g for 10 min at 4°C. The supernatant is centrifuged at 100,000 x g for 1 hr at 4°C. The 100,000 x g  
15 microsomal pellet is resuspended in 0.1 M Tris-HCl, pH 7.4, 10 mM EDTA to approximately 7 mg protein/ml and stored at -80°C.

Microsomal preparations are thawed immediately prior to use, subjected to a brief sonication, and then diluted to a protein concentration of 125 µg/ml in 0.1 M Tris-HCl buffer, pH 7.4 containing  
20 10 mM EDTA, 0.5 mM phenol, 1 mM reduced glutathione and 1 µM hematin. Assays are performed in duplicate in a final volume of 250 µl. Initially, 5 µl of DMSO vehicle or drug in DMSO are added to 20 µl of 0.1 M Tris-HCl buffer, pH 7.4 containing 10 mM EDTA in wells of a 96-deepwell polypropylene titre plate. 200 µl of the microsomal  
25 preparation are then added and pre-incubated for 15 min at room temperature before addition of 25 µl of 1 M arachidonic acid in 0.1 M Tris-HCl and 10 mM EDTA, pH 7.4. Samples are incubated for 40 min at room temperature and the reaction is stopped by the addition of 25 µl of 1 N HCl. Samples are neutralized with 25 µl of 1 N NaOH prior to  
30 quantitation of PGE<sub>2</sub> content by radioimmunoassay (Dupont-NEN or Amersham assay kits). Cyclooxygenase activity is defined as the difference between PGE<sub>2</sub> levels in samples incubated in the presence of arachidonic acid and ethanol vehicle.

- 35 -

### Assay of the activity of purified human COX-2

The enzyme activity is measured using a chromogenic assay based on the oxidation of N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD) during the reduction of PGG<sub>2</sub> to PGH<sub>2</sub> by COX-2 (Copeland et al. (1994) Proc. Natl. Acad. Sci. 91, 11202-11206).

Recombinant human COX-2 is purified from Sf9 cells as previously described (Percival et al (1994) Arch. Biochem. Biophys. 15, 111-118). The assay mixture (180 µL) contains 100 mM sodium phosphate, pH 6.5, 2 mM genapol X-100, 1 µM hematin, 1 mg/ml gelatin, 80-100 units of purified enzyme (One unit of enzyme is defined as the amount of enzyme required to produce an O.D. change of 0.001/min at 610 nm) and 4 µL of the test compound in DMSO. The mixture is pre-incubated at room temperature (22°C) for 15 minutes prior to initiation of the enzymatic reaction by the addition of 20 µL of a sonicated solution of 1 mM AA and 1 mM TMPD in assay buffer (without enzyme or hematin). The enzymatic activity is measured by estimation of the initial velocity of TMPD oxidation over the first 36 sec of the reaction. A non-specific rate of oxidation is observed in the absence of enzyme (0.007 - 0.010 O.D. /min) and is subtracted before the calculation of the % inhibition. IC<sub>50</sub> values are derived from 4-parameter least squares non-linear regression analysis of the log-dose vs % inhibition plot.

### HUMAN WHOLE BLOOD ASSAY

25

#### Rationale

Human whole blood provides a protein and cell-rich milieu appropriate for the study of biochemical efficacy of anti-inflammatory compounds such as selective COX-2 inhibitors. Studies have shown that normal human blood does not contain the COX-2 enzyme. This is consistent with the observation that COX-2 inhibitors have no effect on PGE<sub>2</sub> production in normal blood. These inhibitors are active only after incubation of human whole blood with LPS, which induces COX-2. This assay can be used to evaluate the inhibitory effect of selective

- 36 -

COX-2 inhibitors on PGE<sub>2</sub> production. As well, platelets in whole blood contain a large amount of the COX-1 enzyme. Immediately following blood clotting, platelets are activated through a thrombin-mediated mechanism. This reaction results in the production of thromboxane B<sub>2</sub> (TxB<sub>2</sub>) via activation of COX-1. Thus, the effect of test compounds on TxB<sub>2</sub> levels following blood clotting can be examined and used as an index for COX-1 activity. Therefore, the degree of selectivity by the test compound can be determined by measuring the levels of PGE<sub>2</sub> after LPS induction (COX-2) and TxB<sub>2</sub> following blood clotting (COX-1) in the same assay.

### METHOD

#### Step A: COX-2 (LPS-induced PGE<sub>2</sub> production)

Fresh blood is collected in heparinized tubes by venipuncture from both male and female volunteers. The subjects have no apparent inflammatory conditions and have not taken any NSAIDs for at least 7 days prior to blood collection. Plasma is immediately obtained from a 2mL blood aliquot to use as blank (basal levels of PGE<sub>2</sub>). The remaining blood is incubated with LPS (100 µg/ml final concentration, Sigma Chem, #L-2630 from E. coli; diluted in 0.1% BSA (Phosphate buffered saline) for 5 minutes at room temperature. Five hundred µL aliquots of blood are incubated with either 2µL of vehicle (DMSO) or 2µL of a test compound at final concentrations varying from 10nM to 30µM for 24 hours at 37°C. At the end of the incubation, the blood is centrifuged at 12,000 x g for 5 minutes to obtain plasma. A 100µL aliquot of plasma is mixed with 400µL of methanol for protein precipitation. The supernatant is obtained and is assayed for PGE<sub>2</sub> using a radioimmunoassay kit (Amersham, RPA#530) after conversion of PGE<sub>2</sub> to its methyl oximate derivative according to the manufacturer's procedure.

- 37 -

**Step B: COX-1 (Clotting-induced TxB<sub>2</sub> production)**

Fresh blood is collected into vacutainers containing no anticoagulants. Aliquots of 500 $\mu$ L are immediately transferred to siliconized microcentrifuge tubes preloaded with 2 $\mu$ L of either DMSO or a test compound at final concentrations varying from 10nM to 30 $\mu$ M. The tubes are vortexed and incubated at 37°C for 1 hour to allow blood to clot. At the end of incubation, serum is obtained by centrifugation (12,000 x g for 5 min.). A 100 $\mu$ L aliquot of serum is mixed with 400 $\mu$ L of methanol for protein precipitation. The supernatant is obtained and is assayed for TxB<sub>2</sub> using a enzyme immunoassay kit (Cayman, #519031) according to the manufacturer's instruction.

**RAT PAW EDEMA ASSAY**

**Protocol**

Male Sprague-Dawley rats (150-200 g) are fasted overnight and are given, po, either vehicle (1% methocel or 5% Tween 80) or a test compound. One hr later, a line is drawn using a permanent marker at the level above the ankle in one hind paw to define the area of the paw to be monitored. The paw volume (V<sub>0</sub>) is measured using a plethysmometer (Ugo-Basile, Italy) based on the principle of water displacement. The animals are then injected subplantarly with 50  $\mu$ l of 1% carrageenan solution in saline (FMC Corp, Maine) into the paw using an insulin syringe with a 25-gauge needle (i.e. 500  $\mu$ g carrageenan per paw). Three hr later, the paw volume (V<sub>3</sub>) is measured and the increases in paw volume (V<sub>3</sub> - V<sub>0</sub>) are calculated. The animals are sacrificed by CO<sub>2</sub> asphyxiation and the absence or presence of stomach lesions scored. Data is compared with the vehicle-control values and percent inhibition calculated. All treatment groups are coded to eliminate observer bias.

30



## NSAID-INDUCED GASTROPATHY IN RATS

### Rationale

The major side effect of conventional NSAIDs is their ability to produce gastric lesions in man. This action is believed to be caused by inhibition of COX-1 in the gastrointestinal tract. Rats are particularly sensitive to the actions of NSAIDs. In fact, rat models have been used commonly in the past to evaluate the gastrointestinal side effects of current conventional NSAIDs. In the present assay, NSAID-induced gastrointestinal damage is observed by measuring fecal  $^{51}\text{Cr}$  excretion after systemic injection of  $^{51}\text{Cr}$ -labeled red blood cells. Fecal  $^{51}\text{Cr}$  excretion is a well-established and sensitive technique to detect gastrointestinal integrity in animals and man.

### Methods

Male Sprague Dawley rats (150 - 200 g) are administered orally a test compound either once (acute dosing) or b.i.d. for 5 days (chronic dosing). Immediately after the administration of the last dose, the rats are injected via a tail vein with 0.5 mL of  $^{51}\text{Cr}$ -labeled red blood cells from a donor rat. The animals are placed individually in metabolism cages with food and water *ad lib*. Feces are collected for a 48 h period and  $^{51}\text{Cr}$  fecal excretion is calculated as a percent of total injected dose.  $^{51}\text{Cr}$ -labeled red blood cells are prepared using the following procedures. Ten mL of blood is collected in heparinized tubes via the vena cava from a donor rat. Plasma is removed by centrifugation and replenished with equal volume of HBSS. The red blood cells are incubated with 400 $\mu$  Ci of sodium  $^{51}\text{Cr}$  chromate for 30 min. at 37°C. At the end of the incubation, the red blood cells are washed twice with 20 mL HBSS to remove free sodium  $^{51}\text{Cr}$  chromate. The red blood cells are finally reconstituted in 10 mL HBSS and 0.5 mL of the solution (about 20 $\mu$  Ci) is injected per rat.

- 39 -

## PROTEIN-LOSING GASTROPATHY IN SQUIRREL MONKEYS

### Rationale

- Protein-losing gastropathy (manifested as appearance of circulating cells and plasma proteins in the GI tract) is a significant and dose-limiting adverse response to standard non-steroidal anti-inflammatory drugs (NSAIDs). This can be quantitatively assessed by intravenous administration of  $^{51}\text{CrCl}_3$  solution. This isotopic ion can avidly bind to cell and serum globins and cell endoplasmic reticulum.
- Measurement of radioactivity appearing in feces collected for 24 h after administration of the isotope thus provides a sensitive and quantitative index of protein-losing gastropathy.

### Methods

- Groups of male squirrel monkeys (0.8 to 1.4 kg) are treated by gavage with either 1% methocell or 5% Tween 80 in  $\text{H}_2\text{O}$  vehicles, (3mL/kg b.i.d.) or test compounds at doses from 1 - 100 mg/kg b.i.d. for 5 days. Intravenous  $^{51}\text{Cr}$  ( $5\mu\text{Ci/kg}$  in 1 mL/kg phosphate buffer saline (PBS)) is administered 1 h after the last drug/vehicle dose, and feces collected for 24 h in a metabolism cage and assessed for excreted  $^{51}\text{Cr}$  by gamma-counting. Venous blood is sampled 1 h and 8 h after the last drug dose, and plasma concentrations of drug measured by RP-HPLC.

### 25 LPS-Induced Pyrexia in Conscious Rats

- Male Sprague-Dawley rats (150 - 200 g) were fasted for 16 - 18 h before use. At approximately 9:30 a.m., the animals were placed temporarily in plexiglass restrainers and their baseline rectal temperature was recorded using a flexible temperature probe (YSI series 400) connected to a digital thermometer (Model 08502, Cole Parmer). The same probe and thermometer were used for all animals to reduce experimental error. The animals were returned to their cages after the temperature measurements. At time zero, the rats were

- 40 -

injected intraperitoneally with either saline or LPS (2 mg/kg, Sigma Chem) and the rectal temperature was remeasured at 5, 6 and 7 h following LPS injection. After the measurement at 5 h, when the increase in temperature had reached a plateau, the LPS-injected rats  
5 were given either the vehicle (1% methocel) or a test compound orally to determine whether the compound could reverse the pyrexia. Percent reversal of the pyrexia was calculated using the rectal temperature obtained at 7 h in the control (vehicle-treated) group as the reference (zero reversal) point. Complete reversal of pyrexia to the pre-LPS  
10 baseline value is taken as 100%.

#### LPS-Induced Pyrexia in Conscious Squirrel Monkeys

Temperature probes were surgically implanted under the abdominal  
15 skin in a group of squirrel monkeys (*Saimiri sciureus*) (1.0 - 1.7 kg). This allows for the monitoring of body temperature in conscious, unrestrained monkeys by a telemetric sensing system (Data Sciences International, Minnesota). The animals were fasted and were placed in individual cages for acclimatization 13 - 14 h before use. Electronic  
20 receivers were installed on the side of the cages which pick up signals from the implanted temperature probes. At approximately 9:00 a.m. on the day of the experiment, the monkeys were restrained temporarily in training chairs and were given a bolus I.V. injection of LPS, (6 mg/kg, dissolved in sterile saline). The animals were returned to their  
25 cages and body temperature was recorded continuously every 5 min. Two h after injection of LPS, when the body temperature had increased by 1.5 - 2 C, the monkeys were dosed orally with either vehicle (1% methocel) or a test compound (3 mg/kg). One hundred minutes later, the difference between the body temperature and the baseline value was  
30 determined. Percent inhibition was calculated taking the value in the control group as 0% inhibition.

### Acute Inflammatory Hyperalgesia Induced by Carrageenan in Rats

Experiments were performed using male Sprague Dawley rats (90-110g). Hyperalgesia to mechanical compression of the hind paw was induced by intraplantar injection of carrageenan (4.5 mg into one hind paw) 3 h previously. Control animals received an equivalent volume of saline (0.15 ml intraplantar). A test compound (0.3-30 mg/kg, suspended in 0.5% methocel in distilled water) or vehicle (0.5% methocel) was administered orally (2ml/kg) 2 h after carrageenan. The vocalisation response to compression of the hind paw was measured 1 h later using a Ugo Basile algesiometer.

Statistical analysis for carrageenan-induced hyperalgesia was performed using one-way ANOVA (BMDP Statistical Software Inc.). Hyperalgesia was determined by subtracting the vocalisation threshold in saline injected rats from that obtained in animals injected with carrageenan. Hyperalgesia scores for drug-treated rats were expressed as a percentage of this response. ID<sub>50</sub> values (the dose producing 50% of the maximum observed response) were then calculated by nonlinear least squares regression analysis of mean data using GraFit (Erithacus Software).

### Adjuvant-Induced Arthritis in Rats

Seventy, 6.5-7.5 week old, female Lewis rats (body weight ~146-170 g) were weighed, ear marked, and assigned to groups (a negative control group in which arthritis was not induced, a vehicle control group, a positive control group administered indomethacin at a total daily dose of 1 mg/kg and four groups administered with a test compound at total daily doses of 0.10-3.0 mg/kg) such that the body weights were equivalent within each group. Six groups of 10 rats each were injected into a hind paw with 0.5 mg of *Mycobacterium butyricum* in 0.1 ml of light mineral oil (adjuvant), and a negative control group of 10 rats was not injected with adjuvant. Body weights, contralateral paw volumes (determined by mercury displacement plethysmography) and lateral

- 42 -

- radiographs (obtained under Ketamine and Xylazine anesthesia) were determined before (day -1) and 21 days following adjuvant injection, and primary paw volumes were determined before (day -1) and on days 4 and 21 following adjuvant injection. The rats were anesthetized with an intramuscular injection of 0.03 - 0.1 ml of a combination of Ketamine (87 mg/kg) and Xylazine (13 mg/kg) for radiographs and injection of adjuvant. The radiographs were made of both hind paws on day 0 and day 21 using the Faxitron (45 kVp, 30 seconds) and Kodak X-OMAT TL film, and were developed in an automatic processor.
- Radiographs were evaluated for changes in the soft and hard tissues by an investigator who was blinded to experimental treatment. The following radiographic changes were graded numerically according to severity: increased soft issue volume (0-4), narrowing or widening of joint spaces (0-5) subchondral erosion (0-3), periosteal reaction (0-4), osteolysis (0-4) subluxation (0-3), and degenerative joint changes (0-3). Specific criteria were used to establish the numerical grade of severity for each radiographic change. The maximum possible score per foot was 26. A test compound at total daily doses of 0.1, 0.3, 1, and 3 mg/kg/day, Indomethacin at a total daily dose of 1 mg/kg/day, or vehicle (0.5% methocel in sterile water) were administered per os b.i.d. beginning post injection of adjuvant and continuing for 21 days. The compounds were prepared weekly, refrigerated in the dark until used, and vortex mixed immediately prior to administration.
- Two-factor ('treatment' and 'time') analysis of variance with repeated measures on 'time' were applied to the % changes for body weight and foot volumes and to the rank-transformed radiographic total scores. A *post hoc* Dunnett's test was conducted to compare the effect of treatments to vehicle. A one-way analysis of variance was applied to the thymic and spleen weights followed by the Dunnett's test to compare the effect of treatments to vehicle. Dose-response curves for % inhibition in foot volumes on days 4, 14 and 21 were fitted by a 4-parameter logistic function using a nonlinear least squares' regression. ID<sub>50</sub> was defined as the dose corresponding to a 50% reduction from the vehicle

- 43 -

and was derived by interpolation from the fitted 4-parameter equation.

### PHARMACOKINETICS IN RATS

#### 5 Per Os Pharmacokinetics in Rats

The animals are housed, fed and cared for according to the Guidelines of the Canadian Council on Animal Care.

Male Sprague Dawley rats (325-375 g) are fasted overnight prior to each PO blood level study.

10 The rats are placed in the restrainer one at a time and the box firmly secured. The zero blood sample is obtained by nicking a small (1 mm or less) piece off the tip of the tail. The tail is then stroked with a firm but gentle motion from the top to the bottom to milk out the blood. Approximately 1 mL of blood is collected into a heparinized  
15 vacutainer tube.

Compounds are prepared as required, in a standard dosing volume of 10mL/kg, and administered orally by passing a 16 gauge, 3" gavaging needle into the stomach.

Subsequent bleeds are taken in the same manner as the zero  
20 bleed except that there is no need to nick the tail again. The tail is cleaned with a piece of gauze and milked/stroked as described above into the appropriately labelled tubes.

Immediately after sampling, blood is centrifuged, separated, put into clearly marked vials and stored in a freezer until  
25 analysed.

Typical time points for determination of rat blood levels after PO dosing are:

0, 15min, 30min, 1h, 2h, 4h, 6h

30 After the 4 hr time point bleed, food is provided to the rats *ad libitum*. Water is provided at all times during the study.

- 44 -

**Vehicles:**

The following vehicles may be used in PO rat blood level determinations:

5

PEG 200/300/400: restricted to 2 mL/kg

Methocel 0.5% - 1.0%: 10mL/kg

Tween 80: 10mL/kg

10

Compounds for PO blood levels can be in suspension form. For better dissolution, the solution can be placed in a sonicator for approximately 5 minutes.

For analysis, aliquots are diluted with an equal volume of acetonitrile and centrifuged to remove protein precipitate. The supernatant is injected directly onto a C-18 HPLC column with UV detection. Quantitation is done relative to a clean blood sample spiked with a known quantity of drug. Bioavailability (F) is assessed by comparing area under the curve (AUC) i.v. versus p.o.

20

$$F = \frac{\text{AUC}_{\text{po}}}{\text{AUC}_{\text{iv}}} \times \frac{\text{DOSE}_{\text{iv}}}{\text{DOSE}_{\text{po}}} \times 100\%$$

Clearance rates are calculated from the following relation:

25

$$\text{CL} = \frac{\text{DOSE}_{\text{iv}}(\text{mg/kg})}{\text{AUC}_{\text{iv}}}$$

The units of CL are mL/h•kg (milliliters per hour kilogram)

30 **Intravenous Pharmacokinetics in Rats**

The animals are housed, fed and cared for according to the Guidelines of the Canadian Council on Animal Care.

Male Sprague Dawley (325-375 g) rats are placed in plastic shoe box cages with a suspended floor, cage top, water bottle and food.

- 45 -

The compound is prepared as required, in a standard dosing volume of 1 mL/kg.

Rats are bled for the zero blood sample and dosed under CO<sub>2</sub> sedation. The rats, one at a time, are placed in a primed CO<sub>2</sub> chamber and taken out as soon as they have lost their righting reflex. The rat is then placed on a restraining board, a nose cone with CO<sub>2</sub> delivery is placed over the muzzle and the rat restrained to the board with elastics. With the use of forceps and scissors, the jugular vein is exposed and the zero sample taken, followed by a measured dose of compound which is injected into the jugular vein. Light digital pressure is applied to the injection site, and the nose cone is removed. The time is noted. This constitutes the zero time point.

The 5 min bleed is taken by nicking a piece (1-2 mm) off the tip of the tail. The tail is then stroked with a firm but gentle motion from the top of the tail to the bottom to milk the blood out of the tail. Approximately 1 mL of blood is collected into a heparinized collection vial. Subsequent bleeds are taken in the same fashion, except that there is no need to nick the tail again. The tail is cleaned with a piece of gauze and bled, as described above, into the appropriate labelled tubes.

Typical time points for determination of rat blood levels after I.V. dosing are either:

0, 5 min, 15min, 30min, 1h, 2h, 6h

or 0, 5 min, 30min, 1h, 2h, 4h, 6h.

## Vehicles:

The following vehicles may be used in IV rat blood level determinations:

Dextrose:	1mL/kg
Muculosol 25%:	1mL/kg
DMSO (dimethylsulfoxide):	Restricted to a dose volume of 0.1 mL per animal
PEG 200:	Not more than 60% mixed with 40%



- 46 -

sterile water - 1mL/kg

With Dextrose, either sodium bicarbonate or sodium carbonate can be added if the solution is cloudy.

- 5 For analysis, aliquots are diluted with an equal volume of acetonitrile and centrifuged to remove protein precipitate. The supernatant is injected directly onto a C-18 HPLC column with UV detection. Quantitation is done relative to a clean blood sample spiked with a known quantity of drug. Bioavailability (F) is assessed by  
10 comparing area under the curve (AUC) i.v. versus p.o.

$$F = \frac{AUC_{po}}{AUC_{iv}} \times \frac{DOSE_{iv}}{DOSE_{po}} \times 100\%$$

- 15 Clearance rates are calculated from the following relation:

$$CL = \frac{DOSE_{iv}(mg/kg)}{AUC_{iv}}$$

- 20 The units of CL are mL/h•kg (milliliters per hour kilogram)


### REPRESENTATIVE BIOLOGICAL DATA

- Compounds of the present invention are inhibitors of COX-  
25 2 and are thereby useful in the treatment of COX-2 mediated diseases as enumerated above. The activities of the compounds against cyclooxygenase may be seen in the representative results shown below. In the assay, inhibition is determined by measuring the amount of prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) synthesized in the presence of AA, COX-1 or  
30 COX-2 and a putative inhibitor. The IC<sub>50</sub> values represent the concentration of putative inhibitor required to lower PGE<sub>2</sub> synthesis to 50% of that obtained as compared to the uninhibited control.

Data from three of these biological assays is given for representative compounds along with comparative data for the following

- 47 -

two compounds from World Patent Application 96/10012:



5

Table 3

Example	Cox-2 Whole Blood (IC <sub>50</sub> , μM)	Cox-1 (IC <sub>50</sub> , μM)	U937 (IC <sub>50</sub> , μM)	Selectivity Ratio	Rat Paw Edema (ED <sub>50</sub> , mg/kg)
Aa	7.9	>10		>1.3	>10
Ab	4.9	2.2		0.45	-
1	0.3	1.5		4.4	5.4
3	0.9	1.8		2	-
4	0.3	1		3.3	-
7	1.8	5		2.8	1.7
13	0.5	3		6	-
14	0.7	1.4		2	-
21	1.0	16		16	2.3
23	1.1	>10		>9.1	0.6
32	1.2	>10		>8.3	0.9
45	2.2	>10		>4.5	3.0
46					3.3
47					2.4
59					0.8
71	1.7	>10		>5.8	1.6
73	1.8	7		3.8	2.0

As can be seen from this data, the compounds of the present invention show greater COX-2 selectivity and potency than Aa and Ab. Moreover, the basicity of the pyridine ring in these examples permits the formation of acid salts, resulting in increased water solubility and

10

- 48 -

gives the potential for parenteral administration in aqueous vehicles.

- 49 -

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

- 5 (i) all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C and drying of organics was done using MgSO<sub>4</sub>,
- 10 (ii) evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5-30 mm. Hg) with a bath temperature of up to 60°C,
- 15 (iii) the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only;
- 20 (iv) melting points are uncorrected and 'd' indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations;
- 25 (v) the structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data;
- (vi) yields are given for illustration only;
- 30 (vii) when given, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz or 400 MHz using the indicated solvent; conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc.: in addition "Ar" signifies an aromatic signal;

- 50 -

(viii) chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (litre(s)), mL (millilitres), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)),  
5 r.t. (room temperature).

### EXAMPLE 1

#### 3-(4-Methylsulfonyl)phenyl-2-phenyl-5-trifluoromethylpyridine

10

##### Step 1: 2-Amino-3-bromo-5-trifluoromethylpyridine

To a solution of 2-amino-5-trifluoromethylpyridine (9 g) in acetic acid (75 mL) at r.t. was added bromine (5.8 mL) slowly. After 1 h, the acid was neutralized by the careful addition of sodium hydroxide  
15 (10 N) at 0°C. The resulting orange precipitate was dissolved in ether and washed successively with saturated potassium carbonate, saturated Na<sub>2</sub>SO<sub>3</sub> and brine, dried and concentrated. The residual solid was stirred vigorously in hexane for 1 h to provide, after filtration, the title compound as a white solid (10.2 g).

20

##### Step 2: 2-Amino-3-(4-methylthio)phenyl-5-trifluoromethylpyridine

A mixture of the bromide from Step 1, 4-methylthiobenzene boronic acid (Li, et. al. *J. Med. Chem.* 1995, 38, 4570) (8.5 g), 2M aqueous sodium carbonate (60 mL) and palladium tetrakis(triphenylphosphine) (490 mg) in ethanol/benzene (100 mL, 1:1)  
25 was heated at reflux for 15 h. The mixture was cooled to r.t., diluted with water and extracted with ether. The organics were concentrated and the residue was subjected to stirred vigorously in ether/hexane for 1 h to provide, after filtration, the title compound (11.2 g) as a beige  
30 solid.

- 51 -

**Step 3:**      2-Amino-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl-  
pyridine

A mixture of 2-amino-3-(4-methylthio)phenyl-5-trifluoromethylpyridine (9.7 g), OsO<sub>4</sub> (2 mL of a 4% solution in water) and  
5 NMO (13 g) in acetone/water (60 mL:5 mL) was stirred at r.t. overnight. Saturated aqueous Na<sub>2</sub>SO<sub>3</sub> was then added and the resulting mixture was stirred for 30 min. The acetone was evaporated and the resulting mixture was extracted with ether and ethyl acetate. The combined organics were washed with Na<sub>2</sub>SO<sub>3</sub>, water, brine and then  
10 concentrated. The solid residue was stirred vigorously in hexane and ether for 1 h and then filtered to provide the title compound as a pale yellow solid (9.9 g).

**Step 4:**      2-Chloro-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl-  
pyridine

To a solution of 2-amino-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine (1.2 g) in water/concentrated HCl (9.5 mL:1 mL) at 0°C was added a solution of sodium nitrite (262 mg) in 5 mL water. The mixture was warmed to r.t. and stirred overnight. An  
20 additional 30 mg of sodium nitrite was added and after 3 h the heterogeneous mixture was filtered. A portion of the solid (250 mg) and POCl<sub>3</sub> (110 µL) in DMF (2 mL) was heated at 70°C for 60 h. The mixture was cooled to r.t., diluted with water and extracted with ethyl acetate. The organics were washed with brine, dried and concentrated  
25 to provide the title compound as a pale yellow solid (270 mg) that was used as such in the subsequent reaction.

**Step 5:**      3-(4-Methylsulfonyl)phenyl-2-phenyl-5-trifluoromethyl-  
pyridine

A mixture of 2-chloro-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine (260 mg), benzene boronic acid (113 mg), 2M aqueous sodium carbonate (2.1 mL) and palladium tetrakis(triphenylphosphine) (30 mg) in ethanol/benzene (8 mL, 1:1) was heated at reflux for 24 h. The mixture was cooled to r.t., diluted with water and

- 52 -

extracted with ethyl acetate. The organics were concentrated and the solid residue was subjected to flash chromatography (eluting with hexane/ethyl acetate, 4:1 v/v) to provide the title compound as a white solid, m.p. 191-192°C (215 mg).

5

## EXAMPLE 2

### 2-(3-Chlorophenyl)-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine

10

#### Step 1: 2-Bromo-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine

To a solution of 2-amino-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine from Example 1, Step 3 (2 g) in 48% HBr (25 mL) at 0°C was added bromine (3 mL) and then sodium nitrite (1.1 g) portionwise. After 2 h, the solution was neutralized by the addition of sodium hydroxide (10 N) and then extracted with ethyl acetate. The organics were washed with saturated Na<sub>2</sub>SO<sub>3</sub> and brine, dried and concentrated. Flash chromatography of the residual material (eluting with hexane/ethyl acetate, 7:3 to 3:7 v/v) provided the title compound as a white solid (435 mg).

15

20

#### Step 2: 2-(3-Chlorophenyl)-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine

25

A mixture of 2-bromo-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine (178 mg), 3-chlorophenyl boronic acid (110 mg), potassium phosphate (225 mg) and palladium tetrakis(triphenylphosphine) (20 mg) in dioxane (10 mL) was heated at reflux for 24 h. After cooling to room temperature, the mixture was diluted with water and extracted with ether. The organics were dried and concentrated and the residual material was subjected to flash chromatography (eluting with hexane/ethyl acetate, 7:3 v/v). The solid that was obtained was stirred vigorously in hexane/ether for 1 h to provide the title compound as a pale yellow solid, m.p. 136-237°C (115 mg).

30

- 53 -

EXAMPLE 3

5 2-(4-Chlorophenyl)-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl-  
pyridine

Following the procedures described in Example 1, Step 5, but substituting 4-chlorophenyl boronic acid for benzene boronic acid, the title compound was obtained as a white solid, m.p. 192-193°C (155 mg).

10

EXAMPLE 4

15 2-(4-Fluorophenyl)-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl-  
pyridine

Following the procedures described in Example 1, Step 5, but substituting 4-fluorophenyl boronic acid for benzene boronic acid, the title compound was obtained as a white solid, m.p. 163-164°C (152 mg).

20

EXAMPLE 7

3-(4-Methylsulfonyl)phenyl-2-(3-pyridinyl)-5-trifluoromethylpyridine

25 A mixture of 2-bromo-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine (600 mg) (Example 2, Step 2), diethyl-3-pyridinylborane (255 mg), sodium carbonate (2 M, 2.2 mL) and bis(triphenylphosphine)palladium dibromide (25 mg) in benzene/ethanol (1:1, 32 mL) was heated at reflux for 24 h. After cooling to r.t., the mixture was concentrated, diluted with water and extracted with ethyl acetate. The organics were concentrated and the residual material was  
30 dissolved in 10% HCl/ether. The organic phase was removed and the aqueous phase was adjusted to ~pH 10 by the addition of saturated sodium bicarbonate. The mixture was extracted with ethyl acetate and the combined organics were concentrated and subjected to flash chromatography (eluting with ethyl acetate) to provide the title



- 54 -

compound as a white solid, m.p. 171-172°C (180 mg).

### EXAMPLE 13

#### 5 5-Methyl-3-(4-methylsulfonyl)phenyl-2-phenylpyridine

##### Step 1: 2-Amino-3-bromo-5-methylpyridine

To a solution of 2-amino-5-picoline (5 g) in acetic acid (40 mL) at r.t. was added bromine (2.6 mL) slowly. After 1 h, the acid was  
10 neutralized by the careful addition of sodium hydroxide (10 N) at 0°C. The resulting orange precipitate was dissolved in ether and washed successively with saturated potassium carbonate, saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> and brine, dried and concentrated. Flash chromatography (eluting with hexane/ethyl acetate, 3:2 v/v) of the residual solid provided the title  
15 compound as a pale yellow solid (7.1 g).

##### Step 2: 2-Amino-5-methyl-3-(4-methylsulfonyl)phenylpyridine

Following the procedures described in Example 1, Steps 2 and 3, but substituting 2-amino-3-bromo-5-methylpyridine (7.1 g) from  
20 Step 1 for 2-amino-3-bromo-5-trifluoromethylpyridine, the title compound was obtained as a pale yellow solid (3.7 g).

##### Step 3: 2-Bromo-5-methyl-3-(4-methylsulfonyl)phenylpyridine

Following the procedures described in Example 2, Step 1,  
25 but substituting 2-amino-5-methyl-3-(4-methylsulfonyl)phenyl-pyridine (3 g) from Step 2 for 2-amino-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine, the title compound was obtained as a white solid (2.7 g).

##### 30 Step 4: 5-Methyl-3-(4-methylsulfonyl)phenyl-2-phenylpyridine

Following the procedures described in Example 1, Step 5, but substituting 2-bromo-5-methyl-3-(4-methylsulfonyl)phenylpyridine (300 mg) from Step 3 for 2-chloro-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine, the title compound was obtained as a pale

- 55 -

yellow solid (270 mg).  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  2.42 (s, 3H), 3.03 (s, 3H), 7.19-7.28 (m, 5H), 7.35 (d, 2H), 7.51 (d, 1H), 7.81 (d, 2H), 8.56 (d, 1H).

5

EXAMPLE 142-(4-Chlorophenyl)-5-methyl-3-(4-methylsulfonyl)phenylpyridine

Following the procedures described in Example 3, but substituting 2-bromo-5-methyl-3-(4-methylsulfonyl)phenylpyridine (300 mg) from Example 13, Step 3 for 2-chloro-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine, the title compound was obtained as a white solid, m.p. 155-156°C (125 mg).

15

EXAMPLE 155-Methyl-3-(4-methylsulfonyl)phenyl-2-(3-pyridinyl)pyridineStep 1: Lithium Tri-n-propoxy-3-pyridinylboronate

To a solution of 3-bromopyridine (39.5 g) in ether (800 mL) at -90°C (internal temperature) was added n-BuLi (100 mL, 2.5 M) at a rate so that the internal temperature did not exceed -78°C. The resulting mixture was stirred for 1 h at -78°C and then triisopropoxyborate (59 mL) was added and the resulting mixture was warmed to 0°C. Methanol was added and the mixture was evaporated three times from methanol and then two times from n-propanol. The residue was pumped under high vacuum for 3 days and the resulting foam (76 g of a 1:1 mixture of the title compound:n-propanol) was used as such in the subsequent reaction.

30

Step 2: 5-Methyl-3-(4-methylsulfonyl)phenyl-2-(3-pyridinyl)-pyridine

Following the procedures described in Example 14, but substituting lithium tri-n-propoxy-3-pyridylboronate from Step 1 for 4-chlorophenyl boronic acid, the title compound was obtained as a white

- 56 -

solid, m.p. 166-167°C (2.1 g).

### EXAMPLE 17

#### 5 5-Chloro-2-(4-chlorophenyl)-3-(4-methylsulfonyl)phenylpyridine

##### Step 1: 2-Amino-3-bromo-5-chloropyridine

To a solution of 2-amino-5-chloropyridine (10 g) in acetic acid (75 mL) at r.t. was added bromine (2.6 mL) slowly. After 30 min,  
10 the acid was neutralized by the careful addition of sodium hydroxide (10 N) at 0°C. The resulting orange precipitate was dissolved in ethyl acetate and washed successively with saturated potassium carbonate, saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> and brine, dried and concentrated. Flash  
15 chromatography (eluting with hexane/ethyl acetate, 3:1 v/v) of the residual solid provided the title compound as a pale yellow solid (14.8 g).

##### Step 2: 2-Amino-5-chloro-3-(4-methylsulfonyl)phenylpyridine

Following the procedures described in Example 1, Steps 2  
20 and 3, but substituting 2-amino-3-bromo-5-chloropyridine from Step 1 (5 g) for 2-amino-3-bromo-5-trifluoromethylpyridine, the title compound was obtained as a white solid (5 g).

##### Step 3: 2-Bromo-5-chloro-3-(4-methylsulfonyl)phenylpyridine

25 To a cold (ice bath) solution of 2-amino-5-chloro-3-(4-methylsulfonyl)phenylpyridine (5 g) from Step 2 in water/concentrated HCl (50 mL/10 mL) was added sodium nitrite (1.5 g) in water (10 mL). The resulting mixture was stirred at r.t. for 15 h and the resulting precipitate was removed by filtration and washed successively with  
30 water and CCl<sub>4</sub>. After air drying, the white solid (4.8 g) and POBr<sub>3</sub> (10.5 g) in DMF (40 mL) were heated at 100°C for 2 days. The resulting mixture was poured into ice/water and extracted with ethyl acetate. The aqueous phase was made basic with 1N NaOH and extracted with ethyl acetate. The combined organics were dried and

- 57 -

concentrated. Flash chromatography (eluting with hexane/ethyl acetate, 1:1 v/v) of the residue provided the title compound as a white solid (2.7 g).

5 Step 4:      5-Chloro-2-(4-chloro)phenyl-3-(4-methylsulfonyl)phenyl-pyridine

Following the procedures described in Example 3 but substituting 2-bromo-5-chloro-3-(4-methylsulfonyl)phenylpyridine (300 mg) from Step 3 for 2-chloro-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine, the title compound was obtained as a white solid, m.p. 187-188°C (200 mg).

EXAMPLE 20

15 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-pyridinyl)pyridine

Step 1:      3-Bromo-5-chloro-2-hydroxypyridine

A mixture of 5-chloro-2-hydroxypyridine (100 g) and bromine (40.1 mL) in acetic acid (400 mL) was stirred at r.t. for 1 h. The mixture was poured into 3 L of water and stirred for 30 min then filtered. The residual solid was washed with 2 L of cold water, air dried and then coevaporated with toluene three times and with benzene two times. The white solid (81 g) so obtained was used in the subsequent reaction.

25

Step 2:      2-Benzyloxy-3-bromo-5-chloropyridine

A mixture of 3-bromo-5-chloro-2-hydroxypyridine (81 g), benzyl bromide (52 mL) and silver carbonate (97 g) in benzene (1 L) was heated at 70 °C for 1 h. The mixture was cooled to r.t. and then filtered through a bed of celite. The filtrate was concentrated and the residual off-white solid was recrystallized from hexane to provide the title compound as a white solid (102 g).

- 58 -

**Step 3:     2-Benzyloxy-5-chloro-3-(4-methylsulfonyl)phenylpyridine**

Following the procedures described in Example 1, Steps 2 and 3, but substituting 2-benzyloxy-3-bromo-5-chloropyridine (81 g) from Step 2 for 2-amino-3-bromo-5-trifluoromethylpyridine, the title compound was obtained as a white solid (72 g).

**Step 4:     5-Chloro-2-hydroxy-3-(4-methylsulfonyl)phenylpyridine**

A solution of 2-benzyloxy-5-chloro-3-(4-methylsulfonyl)-phenylpyridine (72 g) in trifluoroacetic acid (250 mL) was stirred at 40°C for 15 min and then poured into ice/water (~1 L). After stirring for 10 min, the white solid was filtered, washed twice with a further 1 L of water and then air dried to provide the title compound.

**Step 5:     2,5-Dichloro-3-(4-methylsulfonyl)phenylpyridine**

The crude 5-chloro-2-hydroxy-3-(4-methylsulfonyl)-phenylpyridine from Step 4 was heated in a sealed bomb at 150°C with POCl<sub>3</sub> (400 mL) for 15 h. After cooling to r.t. the excess POCl<sub>3</sub> was removed by distillation under vacuum. The residue was diluted with ethyl acetate and water and then neutralized with sodium hydroxide (10 N) to ~pH 7. The organics were removed, washed with brine and concentrated. The residual solid was recrystallized from ether to provide the title compound as white solid (61 g).

**Step 6:     Lithium Tri-n-propoxy-2-pyridylboronate**

Following the procedures described in Example 15, Step 1 but substituting 2-bromopyridine (1.9 mL) for 3-bromopyridine, the title compound was prepared as an off-white solid (4.1 g).

**Step 7:     5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-pyridinyl)-pyridine**

A mixture of 2,5-dichloro-3-(4-methylsulfonyl)phenylpyridine (1 g), lithium tri-n-propoxy-2-pyridylboronate (1.22 g), sodium carbonate (5 mL, 2M) and bis(triphenylphosphine)palladium dibromide (520 mg) in toluene (100 mL), isopropanol (10 mL) and

- 59 -

water (25 mL) was heated at reflux for 7 h. The mixture was cooled to r.t., diluted with ethyl acetate and filtered through a bed of celite. The filtrate was extracted with 6 N HCl and the aqueous was washed with ethyl acetate. The aqueous phase was basified to ~pH 10 with 10 N sodium hydroxide and then extracted with ethyl acetate. The organics were washed with brine, dried and concentrated. Flash chromatography (eluting with hexane/ethyl acetate, 1:1 v/v) of the residue provided the title compound as a white solid, m.p. 134-135°C (350 mg).

10

### EXAMPLE 21

#### 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridinyl)pyridine

Following the procedures described in Example 20, Step 7, but substituting lithium tri-n-propoxy-3-pyridinylboronate from Example 15, Step 1 for lithium tri-n-propoxy-2-pyridinylboronate, the title compound was obtained as a white solid, m.p. 168-169°C.

### EXAMPLE 22

#### 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(4-pyridinyl)pyridine

##### Step 1: Lithium Trimethoxy-4-pyridinylboronate

Following the procedures described in Example 15, Step 1 but substituting 4-bromopyridine for 3-bromopyridine. The crude material was used prior to evaporating from n-propanol.

##### Step 2: 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(4-pyridinyl)-pyridine

Following the procedures described in Example 20, Step 7, but substituting lithium trimethoxy-4-pyridinylboronate from Step 1 for lithium tri-n-propoxy-2-pyridinylboronate, the title compound was obtained as a white solid, m.p. 187-188°C.

- 60 -

EXAMPLE 235-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine5 Step 1: Trifluoromethanesulfonic acid 2-methylpyridin-5-yl ester

To a mixture of 5-hydroxy-2-methylpyridine (2 g) and pyridine (1.9 mL) in dichloromethane (100 mL) at 0°C was added trifluoromethanesulfonic acid anhydride (3.4 mL). The mixture was stirred at this temperature for 15 min and then at r.t. for 45 min.

10 Ammonium acetate (25%) was added and the organics were removed and washed with 1N HCl, dried and concentrated. The title compound was obtained as a beige liquid (4 g) that was used as such.

15 Step 2: 2-Methyl-5-trimethylstannylpyridine

A mixture of trifluoromethanesulfonic acid 2-methylpyridin-5-yl ester (2.1 g), hexamethylditin (2.85 g), lithium chloride (1.1 g) and palladium tetrakis(triphenylphosphine) (190 mg) was heated at reflux for 180 min and then cooled to r.t.. The mixture was filtered through a bed of celite, washing with ethyl acetate. The filtrate was  
20 washed twice with 5% potassium fluoride, dried and concentrated. Flash chromatography (eluting with hexane/ethyl acetate, 6:1 v/v) of the residue provided the title compound as a pale yellow oil (1.3 g).

25 Step 3: 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridyl)pyridine

A mixture of 2,5-dichloro-3-(4-methylsulfonyl)phenylpyridine from Example 20, Step 5 (750 mg), 2-methyl-5-trimethylstannylpyridine (1.3 g) and palladium tetrakis(triphenylphosphine) (290 mg) in NMP (10 mL) was heated at 100 °C for 15 h. The mixture was  
30 cooled to r.t., diluted with ethyl acetate and filtered through a bed of celite. The filtrate was washed with water, twice with 5% potassium fluoride and then extracted with 1 N HCl. The aqueous phase was neutralized with 10 N sodium hydroxide and then extracted with ethyl acetate. The organics were concentrated and the residue subjected to

- 61 -

flash chromatography (eluting with ethyl acetate) to provide the title compound as a white solid, m.p. 127-128°C.

#### EXAMPLE 43

5

2-(4-Chlorophenyl)-3-(4-methylsulfonyl)phenylpyridinyl-5-carboxylic acid methyl ester

To a solution of 2-(4-chlorophenyl)-5-methyl-3-(4-methylsulfonyl)phenylpyridine (Example 14, 1.9 g) in t-butanol/water (1:2, 60 mL) at 90°C was added solid potassium permanganate (2.5 g) portionwise over 2 h. The resulting mixture was stirred at 90°C for 15 h and then cooled to r.t.. The mixture was filtered through a bed of celite and the filtrate was acidified to ~pH 2 with 6N HCl. The white precipitate was filtered and then a portion of this material was taken up in THF/dichloromethane. Diazomethane in ether was added to this solution until there was no more bubbling upon its addition. The resulting mixture was concentrated and subjected to flash chromatography (eluting with hexane/ethyl acetate, 1:1 v/v). The title compound was obtained as a white solid, m.p. 216-218°C.

20

#### EXAMPLE 44

2-(4-Chlorophenyl)-3-(4-methylsulfonyl)phenylpyridinyl-5-carboxylic acid

25

To a solution of 2-(4-chlorophenyl)-3-(4-methylsulfonyl)-phenylpyridinyl-5-carboxylic acid methyl ester (140 mg) in ethanol/water (1:1, 10 mL) was added lithium hydroxide (0.35 mL, 3N) and the resulting mixture was stirred at r.t. for 45 min. Saturated sodium bicarbonate was added and the aqueous was extracted with ethyl acetate. The aqueous phase was treated with 3N HCl until ~pH 2 and then was extracted with chloroform. The organics were concentrated to provide the title compound as a white solid, m.p. >300°C (60 mg).

30



- 62 -

EXAMPLE 455-Cyano-2-(4-chlorophenyl)-3-(4-methylsulfonyl)phenylpyridine

To 2-(4-chlorophenyl)-3-(4-methylsulfonyl)phenyl-  
5 pyridinyl-5-carboxylic acid (300 mg) in dichloromethane (10 mL) at  
reflux was added chlorosulfonylisocyanate (0.4 mL). After 90 min at  
reflux, the mixture was cooled to r.t. and then DMF (1.5 mL) was  
added slowly. After 15 min, water was added and the mixture was  
10 extracted with ethyl acetate. The organics were washed with water,  
brine, dried and concentrated. Flash chromatography (eluting with  
ethyl acetate/hexane, 2:1 v/v) of the residue provided the title compound  
as a white solid (100 mg). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.06 (s, 3H),  
7.21-7.28 (m, 4H), 7.37 (d, 2H), 7.90 (d, 2H), 7.96 (d, 1H), 8.94 (d,  
1H).

15

EXAMPLE 465-Chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridyl)pyridine  
hydromethanesulfonate

20 A solution of 5-chloro-3-(4-methylsulfonyl)phenyl-2-(3-  
pyridyl)pyridine (5.31 g, Example 21) in ethyl acetate (100 mL) was  
treated with methanesulfonic acid (1 mL) in ethyl acetate (20 mL)  
dropwise. The resulting precipitate was filtered and dried under  
vacuum to provide the title compound (6.4 g) as a white solid. <sup>1</sup>H NMR  
25 (300 MHz, CD<sub>3</sub>OD) δ 2.68 (s, 3H), 3.15 (s, 3H), 7.60 (d, 2H), 7.96-  
8.00 (m, 3H), 8.14 (d, 1H), 8.47 (dt, 1H), 8.80 (d, 1H), 8.86 (m, 2H).

EXAMPLE 475-Chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridyl)pyridine  
hydrochloride

30 A solution of 5-chloro-3-(4-methylsulfonyl)phenyl-2-(3-  
pyridyl)pyridine (2.05 g, Example 21) in hot ethyl acetate (75 mL) was  
treated with hydrochloric acid (1.5 mL, 4M in dioxane) dropwise. The

- 63 -

resulting precipitate was filtered and dried under vacuum to provide the title compound (2.2 g) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 3.24 (s, 3H), 7.59 (d, 2H), 7.80 (dd, 1H), 7.91 (d, 2H), 8.15 (d, 1H), 8.22 (d, 1H), 8.69 (d, 1H), 8.77 (d, 1H), 8.90 (d, 1H).

5

### EXAMPLE 59

#### 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine Hydrochloride


10           Following the procedure described in Example 47, but substituting 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine (from Example 23) for 5-chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridyl)pyridine, the title compound was obtained as a white solid.

15           <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 2.68 (s, 3H), 3.25 (s, 3H), 7.61 (d, 2H), 7.70 (d, 1H), 7.92 (d, 2H), 8.07 (dd, 1H), 8.21 (d, 1H), 8.54 (d, 1H), 8.88 (d, 1H).

### EXAMPLE 71

20

#### 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-ethyl-5-pyridinyl)pyridine



25   Step 1:    Lithium Tri-n-propoxy-2-ethyl-5-pyridylboronate

Following the procedures described in Example 15 Step 1 but substituting 2-ethyl-5-bromopyridine (Tilley and Zawoiski, *J. Org. Chem.* 1988, 53, 386) (4.6 g) for 3-bromopyridine, the title compound was prepared as a yellow solid.


- 64 -

**Step 2:**     5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-ethyl-5-pyridinyl)pyridine

A mixture of 2,5-dichloro-3-(4-methylsulfonyl)phenyl-pyridine (Example 20 Step 5)(5.6 g), lithium tri-n-propoxy-2-ethyl-5-pyridylboronate (Step 1)(4.0 g), sodium carbonate (17 mL, 2M) and bis(triphenylphosphine)palladium dibromide (420 mg) in toluene (75 mL), ethanol (75 mL) and water (15 mL) was heated at reflux for 7 h. The mixture was cooled to r.t., diluted with ethyl acetate and filtered through a bed of celite. The filtrate was extracted with 6 N HCl and the aqueous was washed with ethyl acetate. The aqueous phase was basified to ~pH 10 with 10 N sodium hydroxide and then extracted with ethyl acetate. The organics were washed with brine, dried and concentrated. Flash chromatography (eluting with hexane/ethyl acetate, 1:1 v/v) of the residue provided the title compound as a white solid (4.0 g). <sup>1</sup>H NMR (500 MHz, acetone-*d*<sub>6</sub>) δ 1.21 (t, 3H), 2.74 (q, 2H), 3.14 (s, 3H), 7.14, (d, 1H), 7.59 (m, 3H), 7.93 (d, 2H), 7.99 (d, 1H), 8.44 (d, 1H), 8.75 (d, 1H).

**EXAMPLE 71 - Alternate Method**

5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-ethyl-5-pyridinyl)pyridine



**Step 1:**     5-Bromo-2-ethylpyridine

280 mL of 5N sodium hydroxide (1.4 mol, 2.09 eq) was added to a solution of 158 g of 2,5-dibromopyridine (0.67 mol, 1 eq) in 1.4 L of THF. To the resulting solution, 700 mL of 1N triethylboron in THF (0.70 mol, 1.04 eq), 195 mg of bis(acetonitrile)palladium(II)

- 65 -

chloride (0.75 mmol, 0.0011 eq) and 414 mg 1,1'-bis(diphenylphosphino)ferrocene (0.75 mmol, 0.0011 eq) were added. The reaction was slowly heated to a very slight reflux for 3 hours. It was then cooled down to 0° and treated sequentially with 140 mL of 5N sodium hydroxide (0.70 mol, 1.04 eq) and 53 mL of 30% hydrogen peroxide (0.70 mol, 1.05 eq) at such a rate that the temperature never exceeded 10° C. The mixture was extracted with ether, and the ether extracts washed with sodium hydroxide, water, brine and dried over MgSO<sub>4</sub>. The ether solution was then concentrated and the brown residue was distilled under vacuum (40° C, 1 Torr) to give 112 g of the title compound as a clear oil slightly contaminated with the starting material and 2,5-diethylpyridine. Yield ~90%. The <sup>1</sup>H NMR is comparable to that reported by J.W. Tilley and S. Zawoiski; *J. Org. Chem.*, 1988,53, 386-390. The material is suitable for use in the next step without further purification.

**Step 2: Lithium Tri-n-propoxy-2-ethyl-5-pyridylboronate**

Following the procedures described in Example 15 Step 1 but substituting 5-bromo-2-ethylpyridine from Step 1 for 3-bromopyridine, the title compound was prepared as a yellow solid.

**Step 3: 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-ethyl-5-pyridinyl)pyridine**

A mixture of 2,5-dichloro-3-(4-methylsulfonyl)phenylpyridine (Example 20 Step 5)(5.6 g), lithium tri-n-propoxy-2-ethyl-5-pyridylboronate (Step 2)(4.0 g), sodium carbonate (17 mL, 2M) and bis(triphenylphosphine)palladium dibromide (420 mg) in toluene (75 mL), ethanol (75 mL) and water (15 mL) was heated at reflux for 7 h. The mixture was cooled to r.t., diluted with ethyl acetate and filtered through a bed of celite. The filtrate was extracted with 6 N HCl and the aqueous was washed with ethyl acetate. The aqueous phase was basified to ~pH 10 with 10 N sodium hydroxide and then extracted with ethyl acetate. The organics were washed with brine, dried and concentrated. Flash chromatography (eluting with hexane/ethyl acetate, 1:1 v/v) of the

- 66 -

residue provided the title compound as a white solid (4.0 g).  $^1\text{H}$  NMR (500 MHz, acetone- $d_6$ )  $\delta$  1.21 (t, 3H), 2.74 (q, 2H), 3.14 (s, 3H), 7.14, (d, 1H), 7.59 (m, 3H), 7.93 (d, 2H), 7.99 (d, 1H), 8.44 (d, 1H), 8.75 (d, 1H).


5

### EXAMPLE 72

5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-ethyl-5-pyridinyl)pyridine  
hydromethanesulfonate

---

10



A solution of 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-ethyl-5-pyridinyl)pyridine (3.4 g, Example 71) in ethyl acetate (40 mL) and ether (100 mL) was treated with methanesulfonic acid (873 mg) in ether (20 mL) dropwise. The resulting precipitate was cooled to  $-20^\circ\text{C}$ , filtered and dried under vacuum to provide the title compound (4.3 g) as a white solid.  $^1\text{H}$  NMR (500 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  1.40 (t, 3H), 2.68 (s, 3H), 3.07 (q, 2H), 3.15 (s, 3H), 7.60 (d, 2H), 7.86 (d, 1H), 7.99 (d, 2H), 8.11 (d, 1H), 8.34 (m, 1H), 8.69 (d, 1H), 8.83 (d, 1H).

15

20

### EXAMPLE 73

5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-cyclopropyl-5-pyridinyl)pyridine

25

$^1\text{H}$  NMR (acetone- $d_6$ )  $\delta$  0.9 (m, 4H), 2.0(m, 1H), 3.14(s, 3H), 7.15(d, 1H), 7.50(dd, 1H), 7.59(m, 2H), 7.95(m, 3H), 8.36(d, 1H), 8.72(d, 1H).

30

- 67 -

EXAMPLE 74

5 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2,6-dimethyl-3-  
pyridinyl)pyridine


Analysis for:	C	H	N
Calculated	61.20	4.60	7.51
Found	61.52	4.52	7.87

10

- 68 -

WHAT IS CLAIMED IS:

1. A compound of Formula I



I

or a pharmaceutically acceptable salt thereof wherein:

$R^1$  is selected from the group consisting of

- (a)  $CH_3$ ,
- (b)  $NH_2$ ,
- (c)  $NHC(O)CF_3$ ,
- (d)  $NHCH_3$ ;

Ar is a mono-, di-, or tri-substituted phenyl or pyridinyl (or the N-oxide thereof), wherein the substituents are chosen from the group

consisting of

- (a) hydrogen,
- (b) halo,
- (c) C<sub>1</sub>-6alkoxy,
- (d) C<sub>1</sub>-6alkylthio,
- (e) CN,
- (f) C<sub>1</sub>-6alkyl,
- (g) C<sub>1</sub>-6fluoroalkyl,
- (h)  $N_3$ ,
- (i)  $-CO_2R^3$ ,
- (j) hydroxy,
- (k)  $-C(R^4)(R^5)-OH$ ,
- (l)  $-C_1-6alkyl-CO_2-R^6$ ,
- (m) C<sub>1</sub>-6fluoroalkoxy;

- 69 -

R<sup>2</sup> is chosen from the group consisting of

- (a) halo,
- (b) C<sub>1</sub>-6alkoxy,
- (c) C<sub>1</sub>-6alkylthio,
- 5 (d) CN,
- (e) C<sub>1</sub>-6alkyl,
- (f) C<sub>1</sub>-6fluoroalkyl,
- (g) N<sub>3</sub>,
- (h) -CO<sub>2</sub>R<sup>7</sup>,
- 10 (i) hydroxy,
- (j) -C(R<sup>8</sup>)(R<sup>9</sup>)-OH,
- (k) -C<sub>1</sub>-6alkyl-CO<sub>2</sub>-R<sup>10</sup>,
- (l) C<sub>1</sub>-6fluoroalkoxy,
- (m) NO<sub>2</sub>,
- 15 (n) NR<sup>11</sup>R<sup>12</sup>,
- (o) NHCOR<sup>13</sup>

R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, are each independantly chosen from the group consisting of

- (a) hydrogen, and
- 20 (b) C<sub>1</sub>-6alkyl,

or R<sup>4</sup> and R<sup>5</sup>, R<sup>8</sup> and R<sup>9</sup> or R<sup>11</sup> and R<sup>12</sup> together with the atom to which they are attached form a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms.

25                    2.     A compound according to Claim 1 wherein Ar is a mono-, di-, or trisubstituted 2-pyridinyl.

                     3.     A compound according to Claim 1 wherein Ar is a mono-, di-, or trisubstituted 3-pyridinyl.

30                    4.     A compound according to Claim 1 wherein R<sup>1</sup> is CH<sub>3</sub> or NH<sub>2</sub>.



- 70 -

5. A compound according to Claim 1 wherein Ar is a mono-, di-, or trisubstituted 2-pyridinyl or 3-pyridinyl and the substituents are selected from the group consisting of

- 5 (a) hydrogen,  
(b) halo,  
(c) C<sub>1</sub>-3alkoxy,  
(d) C<sub>1</sub>-3alkylthio,  
(e) C<sub>1</sub>-3alkyl,  
(f) CF<sub>3</sub>, and  
10 (g) CN.

6. A compound according to Claim 1 wherein R<sup>1</sup> is CH<sub>3</sub> or NH<sub>2</sub>; and

- 15 Ar is a mono-, di-, or trisubstituted 2-pyridinyl or 3-pyridinyl and the substituents are selected from the group consisting of  
(a) hydrogen,  
(b) halo,  
(c) C<sub>1</sub>-3alkoxy,  
(d) C<sub>1</sub>-3alkylthio,  
20 (e) C<sub>1</sub>-3alkyl,  
(f) CF<sub>3</sub>, and  
(g) CN.

7. A compound according to Claim 1 wherein R<sup>2</sup> is

- 25 (a) halo,  
(b) C<sub>1</sub>-4alkoxy,  
(c) CN,  
(d) C<sub>1</sub>-3alkyl,  
(e) C<sub>1</sub>-3fluoroalkyl,  
30 (f) -CO<sub>2</sub>H,  
(g) -C<sub>1</sub>-3alkyl-CO<sub>2</sub>H,  
(h) C<sub>1</sub>-3fluoroalkoxy, or  
(i) NO<sub>2</sub>.

- 71 -

8. A compound according to Claim 1 wherein R<sup>2</sup> is halo, CH<sub>3</sub> or CF<sub>3</sub>.

9. A compound according to Claim 1 wherein  
5 R<sup>1</sup> is CH<sub>3</sub> or NH<sub>2</sub>;  
R<sup>2</sup> is halo, CH<sub>3</sub> or CF<sub>3</sub>; and  
Ar is a mono-, di-, or trisubstituted 2-pyridinyl or 3-pyridinyl and the  
substituents are selected from the group consisting of  
10 (a) hydrogen,  
(b) halo,  
(c) C<sub>1</sub>-3alkoxy,  
(d) C<sub>1</sub>-3alkylthio,  
(e) C<sub>1</sub>-3alkyl,  
(f) CF<sub>3</sub>, and  
15 (g) CN.


10. A compound according to Claim 1 wherein  
R<sup>1</sup> is CH<sub>3</sub> or NH<sub>2</sub>;  
R<sup>2</sup> is halo, CH<sub>3</sub> or CF<sub>3</sub>; and  
20 Ar is a mono- or di- substituted 3-pyridinyl and the substituents are  
selected from the group consisting of  
(a) hydrogen,  
(b) halo,  
(c) C<sub>1</sub>-3alkoxy,  
25 (d) C<sub>1</sub>-3alkylthio,  
(e) C<sub>1</sub>-3alkyl,  
(f) CF<sub>3</sub>, and  
(g) CN.

30 11. A compound according to Claim 1 wherein  
R<sup>1</sup> is CH<sub>3</sub> or NH<sub>2</sub>;  
R<sup>2</sup> is halo, CH<sub>3</sub> or CF<sub>3</sub>; and  
Ar is a mono- or di-substituted phenyl and the substituents are selected  
from the group consisting of

- 72 -

- (a) hydrogen,  
 (b) halo,  
 (c) C<sub>1</sub>-3alkoxy,  
 (d) C<sub>1</sub>-3alkylthio,  
 (e) C<sub>1</sub>-3alkyl,  
 (f) CF<sub>3</sub>, and  
 (g) CN.

12. A compound of formula Ia

**Ia**

or a pharmaceutically acceptable salt thereof wherein

	<b>R<sup>2</sup></b>	<b>Ar</b>
	(1) CF <sub>3</sub>	Ph
15	(2) CF <sub>3</sub>	3-ClC <sub>6</sub> H <sub>4</sub>
	(3) CF <sub>3</sub>	4-ClC <sub>6</sub> H <sub>4</sub>
	(4) CF <sub>3</sub>	4-FC <sub>6</sub> H <sub>4</sub>
	(5) CF <sub>3</sub>	2-(CMe <sub>2</sub> OH)C <sub>6</sub> H <sub>4</sub>
	(6) CF <sub>3</sub>	3-(CMe <sub>2</sub> OH)C <sub>6</sub> H <sub>4</sub>
20	(7) CF <sub>3</sub>	3-pyr
	(8) CF <sub>3</sub>	5-(2-Me)pyr
	(9) CF <sub>3</sub>	5-(3-Br)pyr
	(10) CF <sub>3</sub>	5-(3-Cl)pyr
	(11) CF <sub>3</sub>	5-(2-OMe)pyr
25	(12) CF <sub>3</sub>	2-(5-Br)pyr
	(13) Me	Ph
	(14) Me	4-ClC <sub>6</sub> H <sub>4</sub>
	(15) Me	3-pyr

- 73 -

	(16)	Cl	Ph
	(17)	Cl	4-ClC <sub>6</sub> H <sub>4</sub>
	(18)	Cl	2-(CMe <sub>2</sub> OH)C <sub>6</sub> H <sub>4</sub>
	(19)	Cl	3-(CMe <sub>2</sub> OH)C <sub>6</sub> H <sub>4</sub>
5	(20)	Cl	2-pyr
	(21)	Cl	3-pyr
	(22)	Cl	4-pyr
	(23)	Cl	5-(2-Me)pyr
	(24)	Cl	5-(3-Br)pyr
10	(25)	Cl	5-(3-Cl)pyr
	(26)	Cl	5-(2-OMe)pyr
	(27)	Cl	2-(5-Br)pyr
	(28)	F	Ph
	(29)	F	3-pyr
15	(30)	F	5-(2-Me)pyr
	(31)	Br	Ph
	(32)	Br	3-pyr
	(33)	Br	5-(2-Me)pyr
	(34)	NO <sub>2</sub>	Ph
20	(35)	NO <sub>2</sub>	3-pyr
	(36)	NO <sub>2</sub>	5-(2-Me)pyr
	(37)	OMe	Ph
	(38)	OMe	3-pyr
	(39)	OMe	5-(2-Me)pyr
25	(40)	NHCOMe	Ph
	(41)	NHCOMe	3-pyr
	(42)	NHCOMe	5-(2-Me)pyr
	(43)	CO <sub>2</sub> Me	4-ClC <sub>6</sub> H <sub>4</sub>
	(44)	CO <sub>2</sub> H	4-ClC <sub>6</sub> H <sub>4</sub>
30	(45)	CN	4-ClC <sub>6</sub> H <sub>4</sub>


13. A compound according to Claim 12 wherein the pharmaceutically acceptable salt is an acid salt of citric, hydrobromic, hydrochloric, maleic, methanesulfonic, phosphoric, sulfuric or tartaric

- 74 -

acid.

14. A compound according to Claim 13 wherein the pharmaceutically acceptable salt is an acid salt of hydrochloric or methanesulfonic acid.

15. A compound of formula Ib



Ib

10

15

20

25

	R <sup>2</sup>	Ar
(48)	CF <sub>3</sub>	Ph
(49)	CF <sub>3</sub>	4-ClC <sub>6</sub> H <sub>4</sub>
(50)	CF <sub>3</sub>	4-FC <sub>6</sub> H <sub>4</sub>
(51)	CF <sub>3</sub>	3-pyr
(52)	Me	Ph
(53)	Me	4-ClC <sub>6</sub> H <sub>4</sub>
(54)	Cl	3-pyr
(55)	Cl	5-(2-Me)pyr
(56)	CN	4-ClC <sub>6</sub> H <sub>4</sub>
(71)	Cl	5-(2-ethyl)Pyr
(72)	Cl	5-(2-Et)pyr-MeSO <sub>3</sub> H
(73)	Cl	5-(2-c-Pr)pyr
(74)	Cl	3-(2,6-Me <sub>2</sub> )pyr

16. A compound according to Claim 15 wherein the pharmaceutically acceptable salt is an acid salt of citric, hydrobromic, hydrochloric, maleic, methanesulfonic, phosphoric, sulfuric or tartaric acid.

- 75 -

17. A compound according to Claim 16 wherein the pharmaceutically acceptable salt is an acid salt of hydrochloric or methanesulfonic acid.

5           18. A pharmaceutical composition for treating an inflammatory disease susceptible to treatment with an non-steroidal anti-inflammatory agent comprising:  
a non-toxic therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.

10

          19. A pharmaceutical composition for treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:  
15 a non-toxic therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.


          20. A method of treating an inflammatory disease susceptible to treatment with an non-steroidal anti-inflammatory agent comprising:  
20 administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.

25           21. A method of treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:  
administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to Claim 1.

30

- 76 -

22. A compound according to Claim 1 of formula I



I

wherein:


- 5    **R¹** is selected from the group consisting of
- (a) CH<sub>3</sub>,
  - (b) NH<sub>2</sub>,
  - (c) NHC(O)CF<sub>3</sub>,
  - (d) NHCH<sub>3</sub>;
- 10    **Ar** is a mono-, di-, or trisubstituted pyridinyl (or the N-oxide thereof), wherein the substituents are chosen from the group consisting of
- (a) hydrogen,
  - (b) halo,
  - (c) C<sub>1</sub>-6alkoxy,
  - 15    (d) C<sub>1</sub>-6alkylthio,
  - (e) CN,
  - (f) C<sub>1</sub>-6alkyl,
  - (g) C<sub>1</sub>-6fluoroalkyl,
  - (h) N<sub>3</sub>,
  - 20    (i) -CO<sub>2</sub>R<sup>3</sup>,
  - (j) hydroxy,
  - (k) -C(R<sup>4</sup>)(R<sup>5</sup>)-OH,
  - (l) -C<sub>1</sub>-6alkyl-CO<sub>2</sub>-R<sup>6</sup>,
  - (m) C<sub>1</sub>-6fluoroalkoxy;
- 25    **R²** is chosen from the group consisting of
- (a) halo,
  - (b) C<sub>1</sub>-6alkoxy,
  - (c) C<sub>1</sub>-6alkylthio,

- 77 -

- (d) C<sub>1-6</sub>alkyl,  
 (e) N<sub>3</sub>,  
 (f) -CO<sub>2</sub>H,  
 (g) hydroxy,  
 5 (h) C<sub>1-6</sub>fluoroalkoxy,  
 (i) NO<sub>2</sub>,  
 (j) NR<sup>11</sup>R<sup>12</sup>, and  
 (k) NHCOR<sup>13</sup>,  
 R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, are each independantly chosen from  
 10 the group consisting of  
 (a) hydrogen, and  
 (b) C<sub>1-6</sub>alkyl,  
 or R<sup>4</sup> and R<sup>5</sup> or R<sup>11</sup> and R<sup>12</sup> together with the atom to which they are  
 attached form a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms.

15

23. A compound according to Claim 22 of formula Ic



wherein:

- 20 R<sup>1</sup> is selected from the group consisting of  
 (a) CH<sub>3</sub>,  
 (b) NH<sub>2</sub>,  
 R<sup>2</sup> is chosen from the group consisting of  
 (a) chloro,  
 25 (b) methyl.  
 and wherein there may be one, two or three groups X independently  
 selected from the group consisting of  
 (a) hydrogen,



- 78 -

- 5 (b) halo,  
(c) C<sub>1</sub>-4alkoxy,  
(d) C<sub>1</sub>-4alkylthio,  
(e) CN,  
(f) C<sub>1</sub>-4alkyl,  
(g) CF<sub>3</sub>.


24. A compound according to Claim 23  
wherein:  
10 R<sup>1</sup> is selected from the group consisting of  
(a) CH<sub>3</sub>,  
(b) NH<sub>2</sub>,  
R<sup>2</sup> is chloro,  
15 wherein there is one group X independently selected from the group  
consisting of  
(a) hydrogen,  
(b) F or Cl,  
(c) methyl,  
20 (d) ethyl.

25. A compound according to Claim 24  
wherein:  
25 R<sup>1</sup> is selected from the group consisting of  
(a) CH<sub>3</sub>,  
(b) NH<sub>2</sub>,  
R<sup>2</sup> is chloro,  
wherein there is one group X independently selected from the group  
30 consisting of  
(a) hydrogen,  
(b) F or Cl,  
(c) methyl.

- 79 -

26. A compound according to Claim 25 wherein R<sup>1</sup> is methyl.

27. A compound of formula Ic wherein:



R<sup>1</sup> is CH<sub>3</sub> or NH<sub>2</sub>;

R<sup>2</sup> is

- (a) halo
- (b) C<sub>1</sub>-6alkoxy
- (c) C<sub>1</sub>-6alkylthio
- (d) C<sub>1</sub>-6alkyl
- (e) N<sub>3</sub>
- (f) -CO<sub>2</sub>H
- (g) hydroxy
- (h) C<sub>1</sub>-6fluoroalkoxy
- (i) NO<sub>2</sub>
- (j) NR<sup>11</sup>R<sup>12</sup>
- (k) NHCOR<sup>13</sup>, and

X is hydrogen.

28. A compound according to Claim 1 which is 5-chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridinyl)pyridine or a pharmaceutically acceptable salt thereof.

- 80 -


29. A compound according to Claim 1 which is 5-chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridyl)pyridine hydromethanesulfonate.

5 30. A compound according to Claim 1 which is 5-chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridyl)pyridine hydrochloride.

10 31. A compound according to Claim 1 which is 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-ethyl-5-pyridinyl)pyridine or a pharmaceutically acceptable salt thereof.

15 32. A compound according to Claim 1 which is Chloro-3-(4-methylsulfonyl)phenyl-2-(2-ethyl-5-pyridinyl)pyridine hydromethanesulfonate.

33. A compound of formula Ic wherein:



R<sup>1</sup> is CH<sub>3</sub> or NH<sub>2</sub>,

- 20 R<sup>2</sup> is
- (a) halo,
  - (b) C<sub>1</sub>-3alkoxy,
  - (c) C<sub>1</sub>-3alkylthio,
  - (d) C<sub>1</sub>-3alkyl,
  - (e) N<sub>3</sub>,
  - 25 (f) -CO<sub>2</sub>H,
  - (g) hydroxy,
  - (h) C<sub>1</sub>-3fluoroalkoxy,
  - (i) NO<sub>2</sub>,

- 81 -

- (j) NR<sup>11</sup>R<sup>12</sup>,  
(k) NHCOR<sup>13</sup>, and

X is methyl, ethyl, n-propyl, i-propyl or cyclopropyl.

5           34. A compound according to Claim 33 wherein X is  
methyl.

35. A compound according to Claim 33 which is 5-  
chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine or  
10 a pharmaceutically acceptable salt thereof.

36. A compound according to Claim 33 which is 5-  
chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine  
hydrochloride.

15           37. A compound selected from:

3-(4-Methylsulfonyl)phenyl-2-phenyl-5-  
trifluoromethylpyridine;  
20 2-(3-Chlorophenyl)-3-(4-methylsulfonyl)phenyl-5-  
trifluoromethyl-pyridine;  
2-(4-Chlorophenyl)-3-(4-methylsulfonyl)phenyl-5-  
trifluoromethyl-pyridine;  
25 2-(4-Fluorophenyl)-3-(4-methylsulfonyl)phenyl-5-  
trifluoromethyl-pyridine;  
3-(4-Methylsulfonyl)phenyl-2-(3-pyridinyl)-5-  
trifluoromethylpyridine;  
5-Methyl-3-(4-methylsulfonyl)phenyl-2-phenylpyridine;  
2-(4-Chlorophenyl)-5-methyl-3-(4-methylsulfonyl)  
30 phenylpyridine;  
5-Methyl-3-(4-methylsulfonyl)phenyl-2-(3-pyridinyl)  
pyridine;  
5-Chloro-2-(4-chlorophenyl)-3-(4-methylsulfonyl)  
phenylpyridine;

- 82 -

5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-pyridinyl)  
pyridine;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridinyl)  
pyridine;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(4-pyridinyl)  
pyridine;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-  
pyridinyl)pyridine;  
2-(4-Chlorophenyl)-3-(4-methylsulfonyl)phenylpyridinyl-  
5-carboxylic acid methyl ester;  
2-(4-Chlorophenyl)-3-(4-methylsulfonyl)phenylpyridinyl-  
5-carboxylic acid;  
5-Cyano-2-(4-chlorophenyl)-3-(4-methylsulfonyl)  
phenylpyridine;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridyl)pyridine  
hydromethanesulfonate;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(3-pyridyl)pyridine  
hydrochloride;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-  
pyridinyl)pyridine Hydrochloride;  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-ethyl-5-  
pyridinyl)pyridine; and  
5-Chloro-3-(4-methylsulfonyl)phenyl-2-(2-ethyl-5-  
pyridinyl)pyridine hydromethanesulfonate.

38. Use of a compound according to Claim 1, 28, 29, 30, 31, 32, 35, 36 or 37 in the manufacture of a medicament for the treatment of an inflammatory disease.

39. A pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition comprising a compound according to Claim 1, 28, 29, 30, 31, 32, 35, 36 or 37 and a pharmaceutically acceptable carrier.

- 83 -

40. A pharmaceutical composition which comprises a compound as claimed in any of the Claims 1 through 16 and 22 through 37, and a pharmaceutically acceptable carrier.

5 41. An anti-inflammatory pharmaceutical composition comprising an acceptable, anti-inflammatory amount of a compound of formula (I), as defined in any one of Claims 1 to 11, 22 to 26 or 29 to 32, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

10 42. A compound, or pharmaceutically acceptable salt thereof, according to any one of Claims 1 to 17 or 22 to 37 for use as a selective inhibitor of COX-2.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 97/00486

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D213/34 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 10012 A (DU PONT MERCK PHARMA ;BATT DOUGLAS GUY (US); PINTO DONALD JOSEPH P) 4 April 1996 cited in the application see page 63; table 3 ---	1-42
A	WO 96 16934 A (SEARLE & CO ;REITZ DAVID B (US); LI JINGLIN (US); NORTON MONICA B) 6 June 1996 cited in the application see abstract ---	1-42
P,X	WO 96 24584 A (SEARLE & CO ;WEIER RICHARD M (US); LEE LEN F (US); PARTIS RICHARD) 15 August 1996 see claims; examples -----	1-42



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 October 1997

Date of mailing of the international search report

23. 10. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 97/00486

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 20 and 21  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 97/00486

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9610012 A	04-04-96	US 5593994 A AU 3640995 A CA 2200707 A EP 0783486 A FI 971312 A PL 319385 A	14-01-97 19-04-96 04-04-96 16-07-97 27-03-97 04-08-97
WO 9616934 A	06-06-96	AU 4284196 A EP 0794942 A	19-06-96 17-09-97
WO 9624584 A	15-08-96	AU 4859396 A	27-08-96

*Job Name:*

*...support\_video/doc66/66871.pdf*


*Job Owner Name:*

*.MAG.Senniger*

*Time: 5:06:18 pm      Date: 3-4-2004*

## Table Of Contents

Button Description .....	3
Battery Installation .....	3
Programming Your Universal Remote .....	4
TV .....	4
TV Codes .....	4-5
VCR .....	5
VCR Codes .....	6
DBS .....	7
DBS Codes .....	7
Cable Box .....	8
Cable Box Codes .....	8
DVD•AUX .....	9
DVD Codes .....	9
Programming With Code Search .....	10
Retrieving Codes .....	10
TV Menu .....	11
DBS Menu .....	12
DVD Menu .....	13
Sleep Feature .....	14
Trouble Shooting .....	15
Warranty .....	16



## Programming For TV

1. Manually turn on the TV.

Find the three-digit code for your TV in the code list below.

2. Press and hold the **CODE SEARCH** button until the **INDICATOR LIGHT** lights, then release the **CODE SEARCH** button.
3. Press and release the **TV** button (The **INDICATOR LIGHT** will blink then remain lit).
4. Enter the code using the Number Buttons. After your code is entered, the **INDICATOR LIGHT** will turn off.
5. Aim the remote at your TV and press the **ON•OFF** button. Your TV should turn off.

Note: If your TV does not

## TV Code List

*Job Name:*

*...ft PowerPoint Viewer - collab*

*Job Owner Name:*

*.DJH.Senniger*

*Time: 5:06:33 pm      Date: 3-4-2004*

**James Anglehart**  
**Patent Agent, Partner**

**OGILVY  
RENAULT**  
*Expertise  
par excellence*

# **Preserving US Patent Rights in Light of §103(c) in Collaborations**

**Presented to FPTT National Conference**

**May 28-30, 2003, Ottawa, Ontario, Canada**

The purpose of this document is to provide general information. It does not contain a full analysis of the law nor does it constitute an opinion of Ogilvy Renault or any member of the Firm on the points of law discussed. © Ogilvy Renault 2002-2003  
1107 030602

# Presentation Outline

- Cursory review of patentability criteria in USA
- The 35USC§103(c) problem
- Assessing the risk of a §103(c) danger
- Options for common ownership of patent rights

# Patentability Criteria

- An invention must be new w.r.t. to "prior art"
- Invention must also not be "obvious" or suggested
- What is the "prior art" depends on national patent law
- In the USA, the first-to-invent system provides for very different prior art



# Secret Prior Art

- Outside of USA, limited to non-published, earlier filed patent applications (and to novelty only)
- Under US law, includes non-public information
  - Offer for sale more than one year
  - Public use more than one year
  - Made by earlier inventor
  - Described in US patent application before applicant's invention thereof
- Applies to novelty and obviousness

## **Is secret prior art a problem in collaborations?**

- **In first-to-file, absolute novelty countries, novel means not publicly disclosed**
- **Pre-filing development plus 18-month publication window**
- **Collaborators can join in applications freely**
- **In US, 18-month publication = 30-month §102(b) bar for filing CIP or latest application**
- **Secret prior art from partner is a problem**

# The effect of §102(f)/§103(c)

A invents X, the basis of a new technology

A invites B, B having a special expertise in the area, to collaborate with A on the invention X with an NDA or a verbal agreement of confidentiality.

While the invention X remained confidential, there was no basis for common ownership at the time that B invents its improvement Y

A and B agree on ownership and sharing of the IP (patent rights)

E.G. A will be owner, while B will receive royalties. A files the patent.

- X is prior art to Y in the USA only
- If X is patentable, A can patent it
- If Y is patentable over X, A can patent it in the US, in the same patent application as X's or separately

# The effect of §102(f)/§103(c)

A invents X, the basis of a new technology.

A meets with B, a specialist in the field, to discuss a collaboration to improve X under confidentiality.  
No solutions are discussed, only project management.

A and B agree on common ownership of IP. A will be owner of IP rights  
and B will enjoy royalties.

B invents Y. A files a patent application for X, Y or the combination of X and Y.

- X is not prior art against Y in the US or elsewhere
- The combination of X+Y is patentable in the US

## Origins of 35USC§103(c)

- Prior to 1984, work done by an earlier inventor was citable against work done by separate group of later inventors, even within the same company
- R&D team needed to include base inventors to avoid earlier, "novel" work from being citable
- Generally understood that an improvement made by base inventors and additional inventor was made by "same" inventors

## Origins of 35USC§103(c)

- 35USC§103 was amended in 1984
- Exception for “commonly owned” inventions
- §103(c) was amended again in 1999 to add §102(e) to §102(f) and (g)
- Co-inventorship no longer important, but co-ownership is!

## Application of §103(c) by the Courts

- From 1984 until 1997, there was no Federal Court decision on the scope of the exception
- In *New England Braiding Co. V. A.W. Chesterton Co.*, 23 USPQ2d 1622, the court suggested in 1992 that §102(f)/§103(c) is possible
- In *Gambro Lundia AB v. Baxter Healthcare Corp.*, 42 USPQ2d 1378, the Court of Appeals decided that §102(f)/§103(c) is not possible in April 1997

- Judges Lourie and Rader were involved in both the *Gambro* and *OddzOn* decisions



## Application of §103(c) by the Courts

- No known CAFC decision since
- USPTO has policy to apply *OddzOn* interpretation
- USPTO reminds applicants of duty of disclosure to comply

- From MPEP 8<sup>th</sup> edition (08/2001): ¶ 7.20.02 *Joint Inventors, Common Ownership Presumed*

“This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a)”.

## 37CFR1.56 - Duty to disclose

- Applies to any information obtained from third parties related to the invention
- Applies even if third party is not named as co-inventor
- Failure to supply all material information can invalidate future patent (not discovered until litigation)
- Applies even to confidential information

## What the MPEP thinks of “foreigners”

- Foreign applicants will sometimes combine the subject matter of two or more related applications with different inventors into a single U.S. application naming joint inventors. The examiner will make the assumption, absent contrary evidence, that the applicants are complying with their duty of disclosure if no information is provided relative to invention dates and common ownership at the time the later invention was made.

# What qualifies as "Prior Invention"?


- Providing a suggestion that a problem be solved, without providing the solution itself, is not an invention
- Providing technical data that is known to specialist, but that was not known to the inventor and was use to make an invention, is not an invention
- Often a grey area

# What about co-inventorship?


- What if the improvement is made jointly by the inventor of the base invention with the help of a third party collaborator?
- Base invention is probably not prior art to improvement under §102(e),(f) or (g)/§103
- Not a predictable or reliable "safe harbour"

# Managing the risk – first step

Roadmap to navigating the 35USC§103(c) minefield:  
"When is Common Ownership of Patent Rights Among Collaborative R&D Parties Important to Patentability in the US?"




# Managing the risk – background IP transferred







# Managing the risk



# Managing the risk – foreground IP



# Managing the risk – the result



# The Consequences for R&D Collaboration

- If you care about US patent rights, careful management to avoid a problem is required
- More flexibility with respect to common ownership

## **Consequences:**

**When there is agreement as to common ownership**

- **Agreement or understanding must be in place before collaboration begins**
- **Innovations made by contribution of only one party within purview of R&D collaboration belong to common ownership entity**
- **Close collaboration is beneficial to innovation and thus to value of IP rights**
- **“Obvious” advances during collaboration become patentable**

## Consequences:

When there is no agreement as to common ownership

- Separation of contributions is important: use lab books and meeting minutes to prove who did what
- Only non-obvious advances over other party's work will be patentable in USA, and you will likely need to disclose to Patent Office what the other party contributed to get a valid US patent
- Close collaboration must be discouraged - compartmentalization of R&D encouraged, i.e. offer collaborator a description of problem to be solved, wait for collaborator to provide working solution without any real technical collaboration

## **Common ownership $\neq$ loss of control or revenue**

- Agreement can stipulate the compensation or royalties to be paid by other party when exploiting any part of technology developed by collaboration
- Compensation can be a function of each party's inventive contribution
- Equivalent to “what we invent is ours and what you invent is yours”

# Common ownership agreement

- Must clearly define background and foreground IP
- What to do if both parties have background IP?
- Background and foreground IP to be commonly owned where necessary
- Agreement can allow ownership to pass from one party to the other if required or if main exploiter loses interest
- Owner's right to exploit determined by agreement



## Strategy for handling 103(c)

- If you can negotiate full ownership of IP results of collaboration, do so
- If you cannot, or it is not practical, accept common ownership with favourable conditions set out in the agreement
- Do not begin a collaboration without first assessing the danger and/or trying to settle common ownership

# Questions